FILE NAME: Brown & Root (BR)

DATE: 2000

DOC#: BR012

DOCUMENT DESCRIPTION: Legal - Supplemental Responses to Plaintiff's First Request for Admissions and Second for Production of Documents with Exhibits A&B

CAUSE NO. 29668

LaVELLE MOORE, Individually and as Personal Representative of the Heirs and Estate of WILLIE MOORE, Deceased	§	IN THE DISTRICT COURT
Plaintiffs,	§	
vs.	§	ANGELINA COUNTY, TEXAS
OWENS-CORNING FIBERGLAS CORPORATION, et al	§	
Defendants	§	159TH JUDICIAL DISTRICT

SUPPLEMENTAL RESPONSES TO PLAINTIFFS' FIRST REQUEST FOR ADMISSIONS AND SECOND REQUEST FOR PRODUCTION OF DOCUMENTS TO BROWN & ROOT, USA, INC.

Now comes Brown & Root, USA, Inc. (hereinafter referred to as "Brown & Root"), and files these Supplemental Responses to Plaintiffs' First Request for Admissions and Second Request for Production of Document to Brown & Root, USA, pursuant to the Texas Rules of Civil Procedure.

PRELIMINARY STATEMENT AND PREVIOUSLY FILED GENERAL OBJECTIONS

Brown & Root objects to these discovery requests in their entirety for the simple reason that to date, Plaintiffs have refused to answer any discovery propounded by Brown & Root. Brown & Root served Plaintiffs with its First Interrogatories and First Request for Production of Documents on September 19, 1997, more than two years ago. Plaintiffs have not answered or objected to this discovery. By choosing to answer Master Discovery

EXHIBIT B&R 203

Requests rather than those propounded by this Defendant, Plaintiffs have effectively avoided having to answer any discovery relating to Brown & Root's alleged liability in this case. Brown & Root is not like typical defendants in asbestos cases. Brown & Root never engaged in the manufacture or distribution of the products at issue herein. Rather, Brown & Root engaged in certain construction and/or maintenance activities at certain times during Plaintiff's employment at the Lufkin Paper Mill.

To date, Plaintiffs have provided Brown & Root with absolutely no factual evidence to support their liability claims in this case. The basic premise of every lawsuit is for the plaintiff to state a claim and to pursue discovery on the issues relevant to that claim. Plaintiffs have so far failed to identify any conduct on the part of Brown & Root that caused Willie Moore's injuries. There is no authority for the Plaintiffs to seek discovery when they have no basis to believe that Brown & Root was responsible for their alleged injuries. The Plaintiffs should not be permitted to conduct a massive fishing expedition through use of oppressive discovery requests, without any focus on the specific conduct at issue in this case.

In addition, Brown & Root objects to responding to this discovery for any predecessor, successor, division or subsidiary other than Brown & Root, Inc., the entity that contracted with Champion Paper or its predecessors. Requiring Brown & Root to respond for "any predecessor, successor, division or subsidiary, foreign or domestic," is oppressive, irrelevant and outside the scope of discovery.

Brown & Root also objects to Plaintiff's request that documents responsive to this discovery be produced in compliance with the Minnesota Rules of Civil Procedure. The procedural and substantive laws of Texas, not Minnesota, govern this case.

BROWN & ROOT'S AMENDED RESPONSES
TO PLAINTIFF'S DISCOVERY REQUESTS

REQUEST FOR PRODUCTION NO. 3

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all available contracts and work orders relating to work it performed at the Lufkin Paper Mill. The only Brown & Root contract that mentions asbestos is a subcontract with Excelsior that has been previously produced to Plaintiffs and which is silent as to exactly who is to provide materials. In addition, Brown & Root refers Plaintiffs to the documents produced by Champion to Plaintiffs in this and related litigation, and which contain various invoices evidencing that Champion directly purchased asbestos containing materials for use at the Lufkin Paper Mill. In addition, Brown & Root refers Plaintiffs to Champion's sworn discovery responses in this case wherein Champion admits to purchasing asbestos containing materials, including pipe covering and transite, manufactured by Johns-Manville for use at the Mill. In addition, Champion admits to purchasing asbestos-containing packing from Southwestern Rubber & Packing Co.; Lufkin Rubber & Packing Co.; and, Cottingham, Inc. for use at the Mill.

REQUEST FOR PRODUCTION NO. 4

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all available contracts and work orders relating to work it performed at the Lufkin Paper Mill. The only Brown & Root contract that mentions asbestos is a subcontract with Excelsior that has been previously produced to Plaintiffs and which is silent as to exactly who is to provide materials. In addition, Brown & Root refers Plaintiffs to the documents produced by Champion to Plaintiffs in this and related litigation, and which contain various invoices evidencing that Champion directly purchased asbestos containing materials for use at the Lufkin Paper Mill. In addition, Brown & Root refers Plaintiffs to Champion's sworn discovery responses in this case wherein Champion admits to purchasing asbestos containing material, including pipe covering and transite manufactured by Johns-Manville for use at the Mill. Champion also admits to purchasing asbestos-containing packing from Southwestern Rubber & Packing Co.; Lufkin Rubber & Packing Co.; and, Cottingham, Inc. for use at the Mill.

REQUEST FOR PRODUCTION NO. 5

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, see Brown & Root's supplemental response to Request for Production No. 4.

REQUEST FOR PRODUCTION NO. 6

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, see Brown & Root's supplemental response to Request for Production No. 4.

REQUEST FOR PRODUCTION NO. 7

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all documents relating to its industrial hygiene and safety practices.

REQUEST FOR ADMISSION NO. 8.

Admit or deny:

Brown & Root, or subcontractors retained by Brown & Root, used the following asbestos-containing products during the construction, repair and maintenance of the Champion Paper Mill during the years 1938-1960:

a) Pipe Covering;
b) Block insulation;
c) Refractories/castables;

FILE NAME: Brown & Root (BR)

DATE: 2000

DOC#: BR012

DOCUMENT DESCRIPTION: Legal - Supplemental Responses to Plaintiff's First Request for Admissions and Second for Production of Documents with Exhibits A&B

CAUSE NO. 29668

LaVELLE MOORE, Individually and as Personal Representative of the Heirs and Estate of WILLIE MOORE, Deceased	§	IN THE DISTRICT COURT
Plaintiffs,	§	
vs.	§	ANGELINA COUNTY, TEXAS
OWENS-CORNING FIBERGLAS CORPORATION, et al	§	
Defendants	§	159TH JUDICIAL DISTRICT

SUPPLEMENTAL RESPONSES TO PLAINTIFFS' FIRST REQUEST FOR ADMISSIONS AND SECOND REQUEST FOR PRODUCTION OF DOCUMENTS TO BROWN & ROOT, USA, INC.

Now comes Brown & Root, USA, Inc. (hereinafter referred to as "Brown & Root"), and files these Supplemental Responses to Plaintiffs' First Request for Admissions and Second Request for Production of Document to Brown & Root, USA, pursuant to the Texas Rules of Civil Procedure.

PRELIMINARY STATEMENT AND PREVIOUSLY FILED GENERAL OBJECTIONS

Brown & Root objects to these discovery requests in their entirety for the simple reason that to date, Plaintiffs have refused to answer any discovery propounded by Brown & Root. Brown & Root served Plaintiffs with its First Interrogatories and First Request for Production of Documents on September 19, 1997, more than two years ago. Plaintiffs have not answered or objected to this discovery. By choosing to answer Master Discovery

EXHIBIT B&R 203

Requests rather than those propounded by this Defendant, Plaintiffs have effectively avoided having to answer any discovery relating to Brown & Root's alleged liability in this case. Brown & Root is not like typical defendants in asbestos cases. Brown & Root never engaged in the manufacture or distribution of the products at issue herein. Rather, Brown & Root engaged in certain construction and/or maintenance activities at certain times during Plaintiff's employment at the Lufkin Paper Mill.

To date, Plaintiffs have provided Brown & Root with absolutely no factual evidence to support their liability claims in this case. The basic premise of every lawsuit is for the plaintiff to state a claim and to pursue discovery on the issues relevant to that claim. Plaintiffs have so far failed to identify any conduct on the part of Brown & Root that caused Willie Moore's injuries. There is no authority for the Plaintiffs to seek discovery when they have no basis to believe that Brown & Root was responsible for their alleged injuries. The Plaintiffs should not be permitted to conduct a massive fishing expedition through use of oppressive discovery requests, without any focus on the specific conduct at issue in this case.

In addition, Brown & Root objects to responding to this discovery for any predecessor, successor, division or subsidiary other than Brown & Root, Inc., the entity that contracted with Champion Paper or its predecessors. Requiring Brown & Root to respond for "any predecessor, successor, division or subsidiary, foreign or domestic," is oppressive, irrelevant and outside the scope of discovery.

Brown & Root also objects to Plaintiff's request that documents responsive to this discovery be produced in compliance with the Minnesota Rules of Civil Procedure. The procedural and substantive laws of Texas, not Minnesota, govern this case.

BROWN & ROOT'S AMENDED RESPONSES
TO PLAINTIFF'S DISCOVERY REQUESTS

REQUEST FOR PRODUCTION NO. 3

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all available contracts and work orders relating to work it performed at the Lufkin Paper Mill. The only Brown & Root contract that mentions asbestos is a subcontract with Excelsior that has been previously produced to Plaintiffs and which is silent as to exactly who is to provide materials. In addition, Brown & Root refers Plaintiffs to the documents produced by Champion to Plaintiffs in this and related litigation, and which contain various invoices evidencing that Champion directly purchased asbestos containing materials for use at the Lufkin Paper Mill. In addition, Brown & Root refers Plaintiffs to Champion's sworn discovery responses in this case wherein Champion admits to purchasing asbestos containing materials, including pipe covering and transite, manufactured by Johns-Manville for use at the Mill. In addition, Champion admits to purchasing asbestos-containing packing from Southwestern Rubber & Packing Co.; Lufkin Rubber & Packing Co.; and, Cottingham, Inc. for use at the Mill.

REQUEST FOR PRODUCTION NO. 4

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all available contracts and work orders relating to work it performed at the Lufkin Paper Mill. The only Brown & Root contract that mentions asbestos is a subcontract with Excelsior that has been previously produced to Plaintiffs and which is silent as to exactly who is to provide materials. In addition, Brown & Root refers Plaintiffs to the documents produced by Champion to Plaintiffs in this and related litigation, and which contain various invoices evidencing that Champion directly purchased asbestos containing materials for use at the Lufkin Paper Mill. In addition, Brown & Root refers Plaintiffs to Champion's sworn discovery responses in this case wherein Champion admits to purchasing asbestos containing material, including pipe covering and transite manufactured by Johns-Manville for use at the Mill. Champion also admits to purchasing asbestos-containing packing from Southwestern Rubber & Packing Co.; Lufkin Rubber & Packing Co.; and, Cottingham, Inc. for use at the Mill.

REQUEST FOR PRODUCTION NO. 5

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, see Brown & Root's supplemental response to Request for Production No. 4.

REQUEST FOR PRODUCTION NO. 6

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, see Brown & Root's supplemental response to Request for Production No. 4.

REQUEST FOR PRODUCTION NO. 7

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all documents relating to its industrial hygiene and safety practices.

REQUEST FOR ADMISSION NO. 8.

Admit or deny:

Brown & Root, or subcontractors retained by Brown & Root, used the following asbestos-containing products during the construction, repair and maintenance of the Champion Paper Mill during the years 1938-1960:

a) Pipe Covering;
b) Block insulation;
c) Refractories/castables;

d) Insulating spray;
e) Gaskets;
f) Packing;
g) Fireproofing;
h) Joint Compound;
i) Millboard;
j) Transite pipe
k) Plaster; and
i) Asbestos cloth

SUPPLEMENTAL ANSWER: Subject to all previously filed objections, Willie Moore's employer, the Champion Paper Mill, was responsible for the design of the Paper Mill and issued specifications and engineering drawings that contractors, including Brown & Root, were bound by if awarded the work. Brown & Root has produced all contracts and work orders for work performed at the Champion Paper Mill. No Brown & Root contract with Champion specifically refers to the use of asbestos. To the extent that Brown & Root workers may have had to use asbestos-containing materials at some point in time during construction and renovation of the Champion Paper Mill, such use was incidental to the work Brown & Root was hired to perform. Moreover, the evidence indicates that Champion purchased the materials from insulation manufacturers and distributors, like Johns-Manville. *See* Champion's sworn discovery responses in this case as well as documents produced by Champion to Plaintiffs in this and related litigation.

REQUEST FOR PRODUCTION NO. 8

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all available contracts and work orders relating to work it performed at the Lufkin Paper Mill. The only Brown & Root contract that mentions asbestos is a subcontract with Excelsior that has been previously produced to Plaintiff. In addition, Brown & Root refers Plaintiffs to the documents produced by Champion to Plaintiffs in this and related litigation, and which contain various invoices evidencing that Champion directly purchased asbestos containing materials for use at the Lufkin Paper Mill. In addition, Brown & Root refers Plaintiffs to Champion's sworn discovery responses in this case wherein Champion admits to purchasing asbestos containing material, including pipe covering and transite manufactured by Johns-Manville for use at the Mill. Champion also admits to purchasing asbestos-containing packing from Southwestern Rubber & Packing Co.; Lufkin Rubber & Packing Co.; and, Cottingham, Inc. for use at the Mill.

REQUEST FOR ADMISSION NO. 9.

Admit or deny:

Brown & Root, or subcontractors retained by Brown & Root, obtained the following asbestos-containing products during the construction, repair and maintenance of the Champion Paper Mill during the years 1938-1960:

a) Pipe Covering;
b) Block insulation;
c) Refractories/castables;
d) Insulating spray;
e) Gaskets;
f) Packing;
g) Fireproofing;
h) Joint Compound;
i) Millboard;
j) Transite pipe
k) Plaster; and
i) Asbestos cloth

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, see Brown & Root's supplemental response to Request for Admission No. 8, above.

REQUEST FOR PRODUCTION NO. 9.

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all available contracts and work orders relating to work it performed at the Lufkin Paper Mill. The only Brown & Root contract that mentions asbestos is a subcontract with Excelsior that has been previously produced to Plaintiffs. In addition, Brown & Root refers Plaintiffs to the documents produced by Champion to Plaintiffs in this and related litigation, and which contain various invoices evidencing that Champion directly purchased asbestos containing materials for use at the Lufkin Paper Mill. In addition, Brown & Root refers Plaintiffs to Champion's sworn discovery responses in this case wherein Champion admits to purchasing asbestos containing material, including pipe covering and transite, manufactured by Johns-Manville for use at the Mill. Champion also admits to purchasing asbestos-containing packing from Southwestern Rubber & Packing Co.; Lufkin Rubber & Packing Co.; and, Cottingham, Inc. for use at the Mill.

REQUEST FOR ADMISSION NO. 10.

Admit or deny:

Brown & Root, or subcontractors retained by Brown & Root, used the following asbestos-containing products during the construction, repair and maintenance of the Champion Paper Mill during the years 1960-1972:

a) Pipe Covering;
b) Block insulation;
c) Refractories/castables;
d) Insulating spray;
e) Gaskets;
f) Packing;
g) Fireproofing;
h) Joint Compound;
i) Millboard;
j) Transite pipe
k) Plaster; and
i) Asbestos cloth

SUPPLEMENTAL ANSWER: Subject to all previously filed objections, see Brown & Root's supplemental response to Request for Admission No. 8, above.

REQUEST FOR PRODUCTION NO. 10

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all available contracts and work orders relating to work it performed at the Lufkin Paper Mill. The only Brown & Root contract that mentions asbestos is a subcontract with Excelsior that has been previously produced to Plaintiffs. In addition, Brown & Root refers Plaintiffs to the documents produced by Champion to Plaintiffs in this and related litigation, and which contain various invoices evidencing that Champion directly purchased asbestos containing materials for use at the Lufkin Paper Mill. In addition, Brown & Root refers Plaintiffs to Champion's sworn discovery responses in this case wherein Champion admits to purchasing asbestos containing material, including pipe covering and transite, manufactured by Johns-Manville for use at the Mill. Champion also admits to purchasing asbestos-containing packing from

Southwestern Rubber & Packing Co.; Lufkin Rubber & Packing Co.; and, Cottingham, Inc. for use at the Mill.

REQUEST FOR ADMISSION NO. 11.

Admit or deny:

Brown & Root, or subcontractors retained by Brown & Root, obtained the following asbestos-containing products during the construction, repair and maintenance of the Champion Paper Mill during the years 1960-72:

a) Pipe Covering;
b) Block insulation;
c) Refractories/castables;
d) Insulating spray;
e) Gaskets;
f) Packing;
g) Fireproofing;
h) Joint Compound;
i) Millboard;
j) Transite pipe
k) Plaster; and
i) Asbestos cloth

SUPPLEMENTAL ANSWER: Subject to all previously filed objections, see Brown & Root's supplemental response to Request for Admission No. 8, above.

REQUEST FOR PRODUCTION NO. 11:

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all available contracts and work orders relating to work it performed at the Lufkin Paper Mill. The only Brown & Root contract that mentions asbestos is a subcontract with Excelsior that has been previously produced to Plaintiffs. In addition, Brown & Root refers Plaintiffs to the documents produced by Champion to Plaintiffs in this and related litigation, and which contain various invoices evidencing that Champion directly purchased asbestos containing materials for use at the Lufkin Paper Mill. In addition, Brown & Root refers Plaintiffs to Champion's sworn discovery responses in this case wherein Champion admits to purchasing asbestos containing material, including pipe covering and transite, manufactured by Johns-Manville for use at the Mill. Champion also admits to purchasing asbestos-containing packing from

Southwestern Rubber & Packing Co.; Lufkin Rubber & Packing Co.; and, Cottingham, Inc. for use at the Mill.

REQUEST FOR PRODUCTION NO. 13

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, all responsive documents have been previously produced to Plaintiffs.

REQUEST FOR PRODUCTION NO. 14

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 15

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 16

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 17

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL ANSWER: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 18

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 19

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 20

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 21

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 22

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 23

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 24

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 25

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 26

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all available contracts and work orders relating to work it performed at the Lufkin Paper Mill. The only Brown & Root contract that mentions asbestos is a subcontract with Excelsior that has been previously produced to Plaintiffs. In addition, Brown & Root refers Plaintiffs to the documents produced by Champion to Plaintiffs in this and related litigation, and which contain various invoices evidencing that Champion directly purchased asbestos containing materials for use at the Lufkin Paper Mill. In addition, Brown & Root refers Plaintiffs to Champion's sworn discovery responses in this case wherein Champion admits to purchasing asbestos containing material, including pipe covering and transite, manufactured by Johns-Manville for use at the Mill. Champion also admits to purchasing asbestos-containing packing from Southwestern Rubber & Packing Co.; Lufkin Rubber & Packing Co.; and, Cottingham, Inc. for use at the Mill.

REQUEST FOR PRODUCTION NO. 27

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all available contracts and work orders relating to work it performed at the Lufkin Paper Mill. The only Brown & Root contract that mentions asbestos is a subcontract with Excelisor that has been previously produced to Plaintiffs. In addition, Brown & Root refers Plaintiffs to the documents produced by Champion to Plaintiffs in this and related litigation, and which contain various invoices evidencing that Champion directly purchased asbestos containing materials for use at the Lufkin Paper Mill. In addition, Brown & Root refers Plaintiffs to Champion's sworn discovery responses in this case wherein Champion admits to purchasing asbestos containing

material, including pipe covering and transite, manufactured by Johns-Manville for use at the Mill. In addition, Champion admits to purchasing asbestos-containing packing from Southwestern Rubber & Packing Co.; Lufkin Rubber & Packing Co.; and, Cottingham, Inc. for use at the Mill.

REQUEST FOR PRODUCTION NO. 28

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all available contracts and work orders relating to work it performed at the Lufkin Paper Mill. The only Brown & Root contract that mentions asbestos is a subcontract with Excelsior that has been previously produced to Plaintiffs. In addition, Brown & Root refers Plaintiffs to the documents produced by Champion to Plaintiffs in this and related litigation, and which contain various invoices evidencing that Champion directly purchased asbestos containing materials for use at the Lufkin Paper Mill. In addition, Brown & Root refers Plaintiffs to Champion's sworn discovery responses in this case wherein Champion admits to purchasing asbestos containing material, including pipe covering and transite, manufactured by Johns-Manville for use at the Mill. In addition, Champion admits to purchasing asbestos-containing packing from Southwestern Rubber & Packing Co.; Lufkin Rubber & Packing Co.; and, Cottingham, Inc. for use at the Mill.

REQUEST FOR PRODUCTION NO. 29

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all available contracts and work orders relating to work it performed at the Lufkin Paper Mill. The only Brown & Root contract that mentions asbestos is a subcontract with Excelsior that has been previously produced to Plaintiffs. In addition, Brown & Root refers Plaintiffs to the documents produced by Champion to Plaintiffs in this and related litigation, and which contain various invoices evidencing that Champion directly purchased asbestos containing materials for use at the Lufkin Paper Mill. In addition, Brown & Root refers Plaintiffs to Champion's sworn discovery responses in this case wherein Champion admits to purchasing asbestos containing

material, including pipe covering and transite, manufactured by Johns-Manville for use at the Mill. In addition, Champion admits to purchasing asbestos-containing packing from Southwestern Rubber & Packing Co.; Lufkin Rubber & Packing Co.; and, Cottingham, Inc. for use at the Mill.

REQUEST FOR PRODUCTION NO. 30

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all available contracts and work orders relating to work it performed at the Lufkin Paper Mill. The only Brown & Root contract that mentions asbestos is a subcontract with Excelsior that has been previously produced to Plaintiffs. In addition, Brown & Root refers Plaintiffs to the documents produced by Champion to Plaintiffs in this and related litigation, and which contain various invoices evidencing that Champion directly purchased asbestos containing materials for use at the Lufkin Paper Mill. In addition, Brown & Root refers Plaintiffs to Champion's sworn discovery responses in this case wherein Champion admits to purchasing asbestos containing material, including pipe covering and transite, manufactured by Johns-Manville for use at the Mill. Champion also admits to purchasing asbestos-containing packing from Southwestern Rubber & Packing Co.; Lufkin Rubber & Packing Co.; and, Cottingham, Inc. for use at the Mill.

REQUEST FOR PRODUCTION NO. 31

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all available contracts and work orders relating to work it performed at the Lufkin Paper Mill. The only Brown & Root contract that mentions asbestos is a subcontract with Excelsior that has been previously produced to Plaintiffs. In addition, Brown & Root refers Plaintiffs to the documents produced by Champion to Plaintiffs in this and related litigation, and which contain various invoices evidencing that Champion directly purchased asbestos containing materials for use at the Lufkin Paper Mill. In addition, Brown & Root refers Plaintiffs to Champion's sworn discovery responses in this case wherein Champion admits to purchasing asbestos containing material, including pipe covering and transite, manufactured by Johns-Manville for use at the Mill. Champion also admits to purchasing asbestos-containing packing from Southwestern Rubber & Packing

Co.; Lufkin Rubber & Packing Co.; and, Cottingham, Inc. for use at the Mill.

REQUEST FOR PRODUCTION NO. 32

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 33

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 34

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 37

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 38

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 39

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 40

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR ADMISSION NO. 41

Admit or deny:

Brown & Root, or its employees acting in the course and scope of their employment, was a member of the National Safety Council during the following years:

a) 1950
b) 1951
c) 1952
d) 1953
e) 1954
f) 1955
g) 1956

h) 1957
i) 1958
j) 1959
k) 1960
1)1961
m) 1962
n) 1963
o)1964
p) 1965
q) 1966
r) 1967
s) 1968
t) 1969
u) 1970
v) 1971
w) 1972
x) 1973
y) 1974
z) 1975

SUPPLEMENTAL ANSWER: Subject to all previously filed objections, Brow & Root admits that certain employees were individual members of the National Safety Council for a short period of time in 1961 (5 months), 1967 (2 weeks) and 1972-1975, however, Brown & Root denies that these individual memberships in the National Safety Council were in any way related to the individual employees' employment with Brown & Root. The first record of a Brown & Root corporate membership in the National Safety Council is for 1995. The remainder of this request is denied.

REQUEST FOR PRODUCTION NO. 41

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR ADMISSION NO. 42.

Admit or deny:

During each of the following years, Brown & Root, was one of the top ten contractors in the United States, when measured in terms of gross revenues:

a) 1960
b) 1961
c) 1962
d) 1963
e) 1964
f) 1965
g) 1966
h) 1967
i) 1968
j) 1969
k) 1970
1)1971
m) 1972
n) 1973
o)1974
p) 1975

SUPPLEMENT ANSWER: Subject to all previously filed objections, Brown & Root admits that it was among the top 10 contractors in the U.S. from 1962-1965 and 1968-1974 in terms of new business contracts. Brown & Root denies this Request for 1960-1961. Further, Brown & Root states that, after reasonable inquiry, the information available is insufficient to permit Brown & Root to admit or deny this Request for 1966 and 1967. Therefore, this Request is denied for 1966 and 1967.

REQUEST FOR PRODUCTION NO. 42

If you responded to this Request for Admission with anything other than an unqualified admission, please produce all documents and tangible items that support, refute or relate to the Request and your response.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 44

Please produce a current curriculum vitae for the following experts, designated by you to testify at the trial of this case:

John Pendergrass
Phillip Cagle
Francis Weir
Raymond Heit
Marcus Bond

John Hodges
Sam Cade
Dr. Hiram Bismar
Dr. William Miller
Dr. Robert Ross

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has attached all available curricula vitae to these responses as Exhibit "A."

REQUEST FOR PRODUCTION NO. 45

For each of the expert witnesses designated in your answer to Interrogatory No. 4, please produce copies of each deposition or transcription of trial testimony given by that expert during the past three years.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Plaintiffs already have in their possession prior testimony of the witnesses listed.

REQUEST FOR PRODUCTION NO. 46

Please produce any reports produced in this case by any of the experts designated in your answer to Interrogatory No. 4.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, see Exhibit "B," hereto.

REQUEST FOR PRODUCTION NO. 47

Please produce any photographs, inspection reports, notes, summaries, reports, evaluations, videotapes or other documents produced during any inspections conducted by you, or on your behalf, of the premises in question in this case. This request specifically includes, but is not limited to, the production of any photographs, inspection reports, notes, summaries, reports, evaluations, videotapes or other documents which relate to John Pendergrass's inspection of the premises in question, referenced in your February 8, 1999 supplemental answer to Interrogatory No. 4(c)(1).

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all items responsive to this Request.

REQUEST FOR PRODUCTION NO. 49

Please produce all documents reviewed by Raymond Heit concerning the design, engineering and construction of paper mills like the Champion Paper Mill at issue in this case, as well as any documents containing "facts Defendants work at the various locations at issue in this case" [sic], which facts are referenced in your February 8, 1999 supplemental answer to Interrogatory No. 4(c)(5).

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root refers Plaintiffs to the contracts and work orders for the Lufkin Paper Mill previously produced. In addition, Brown & Root refers Plaintiffs to the documents produced to Plaintiffs by Champion in this and related litigation.

REQUEST FOR PRODUCTION NO. 51

Please produce all documents reviewed by John Hodges concerning the design, engineering and construction of paper mills like the Champion Paper Mill at issue in this case, as well as any documents containing "facts Defendants work at the various locations at issue in this case" [sic], which facts are referenced in your February 8, 1999 supplemental answer to Interrogatory No. 4(c)(7).

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced all documents responsive to this Request. Specifically, John Hodges has reviewed the Brown & Root contract for construction at the Lufkin Paper Mill as well as work orders issued pursuant to those contracts.

REQUEST FOR PRODUCTION NO. 55

Please produce the following documents, which you have designated in answer to Interrogatory No. 15 as exhibits you intend to use at the trial of this case:

-"Economic Analysis of the Proposed Revisions to the OSHA Asbestos Standards for Construction and General Industry, July, 1990" (your Exhibit #7)

-"industrial hygiene reports" (your Exhibit # 18)

-"Various corporate and/or product documents of Brown & Root, Inc., if any" (your Exhibit #19)

-"Brown & Root, Inc. Industrial Hygiene Library Index" (your Exhibit #31)

-"Brown & Root, Inc. contract documents, if any" (your Exhibit #41)

-"Corporate records from all work sites/employers where Plaintiff/s claim/s exposure, including but not limited to photographs, maps, charts, air sampling" (your Exhibit #50).

-"Affidavit of the National Safety Council" (your Exhibit #53)

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs documents responsive to this Request.

REQUEST FOR PRODUCTION NO. 56

Please produce copies of all contract documents, including but not limited to bids, proposals, correspondence, contracts, concerning all work performed by Brown & Root at the Southland/Champion Paper Mill in Lufkin, Texas, during the years 1935-1995.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all documents responsive to this Request.

REQUEST FOR PRODUCTION NO. 57

Please produce a 1998 annual report for Haliburton.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all documents responsive to this Request.

REQUEST FOR PRODUCTION NO. 60

Please produce all dust and air monitoring records, including all laboratory reports issued to report the results of that monitoring, collected at the Champion Paper Mill jobsite in Lufkin, Texas during the years 1935-1996.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has already produced various Champion and state regulatory documents that are responsive to this Request. Brown & Root suggests that the better source for this information would be Moore's employer and the premises owner, St. Regis/Southland/Champion, as it was ultimately responsible for air monitoring.

REQUEST FOR PRODUCTION NO. 62

Please produce the entire jobsite file for each job performed by Brown & Root at the Southland/Champion Paper Mill jobsite in Lufkin, Texas, during the years 1935-1996.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced all contract and work orders relating to work it performed at the Champion Paper Mill.

REQUEST FOR PRODUCTION NO. 63

Please produce each and every written records retention/destruction program used at Brown & Root during the years 1950-present.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all responsive documents to Plaintiffs.

REQUEST FOR PRODUCTION NO. 65

Please produce all contracts, written agreements, job proposals and bidding documents for the construction and/or maintenance projects performed at the Southland/Champion Paper Mill in Lufkin, Texas, during the years 1935-1996, including but not limited to those bearing the following Brown & Root job numbers:

27-325	27-342
27-413	27-414
27-447	27-463
27-541	27-4009
27-4041	27-4042
27-4051	27-4054
27-4058	27-4067
27-4087	27-4088
27-4091	27-4106
27-	27-4534
	27-5421
	27-0021
	27-5268
	02
	6029-101
	6029-107
	1063

4270
27-
5138
27-
5424
27-
422
1-36
602
9-
104
602
9-
105
1041
1080
1101

1088
4104-
4961

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has already produced all contracts and work orders relating to work it performed at the Champion Paper Mill.

REQUEST FOR PRODUCTION NO. 73

Please produce all invoices, sales receipts, purchase orders, and all other documents, reflecting the purchase and/or acquisition of asbestos products used by Brown & Root for construction or maintenance at the Southland/Champion Paper Mill in Lufkin, Texas, during the years 1935-present.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all available contracts and work orders relating to work it performed at the Lufkin Paper Mill. The only Brown & Root contract that mentions asbestos is a subcontract with Excelsior that has been previously produced to Plaintiffs and which is silent as to exactly who is to provide materials. In addition, Brown & Root refers Plaintiffs to the documents produced by Champion to Plaintiffs in this and related litigation, and which contain various invoices evidencing that Champion directly purchased asbestos containing materials for use at the Lufkin Paper Mill. In addition, Brown & Root refers Plaintiffs to Champion's sworn discovery responses in this case wherein Champion admits to purchasing asbestos containing material, including pipe covering and transite manufactured by Johns-Manville for use at the Mill. Champion also admits to purchasing asbestos-containing packing from Southwestern Rubber & Packing Co.; Lufkin Rubber & Packing Co.; and, Cottingham, Inc. for use at the Mill.

REQUEST FOR PRODUCTION NO. 74

Please produce all documents relating to or documenting Brown & Root's ownership interest in the Champion Paper Mill in Lufkin, Texas.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all documents responsive to this request.

REQUEST FOR PRODUCTION NO. 75

Please produce all documents relating to or documenting Herman Brown's or George R. Brown's ownership interest and/or financial interest in the Southland/Champion Paper Mill in Lufkin, Texas.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all documents responsive to this request.

REQUEST FOR PRODUCTION NO. 76

Please produce all documents relating to or documenting any capital contributions or other financing provided by Herman Brown, George R. Brown and/or Brown & Root to Southland Paper for the construction and/or renovation and/or upgrading of the paper mill in Lufkin, Texas, which mill was later owned by Champion Paper.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all documents responsive to this request.

REQUEST FOR PRODUCTION NO. 77

Please produce all documents relating to or evidencing the participation by Brown & Root personnel in the management of the paper mill in Lufkin, Texas, including, but not limited to, documents relating to George R. Brown's position on the board of the mill, as well as documents reflecting in any way George R. Brown's participant as an officer or director of that mill.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has produced all documents responsive to this request.

REQUEST FOR PRODUCTION NO. 78

Please produce all documents relating to the initial construction of the Southland/Champion paper mill in Lufkin, Texas, including but not limited to blue prints, designs, specifications, construction contracts, bid documents, letters of intent, etc.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all available contracts and work orders relating to work it performed at the Lufkin Paper Mill. The only Brown & Root contract that mentions asbestos is a subcontract with Excelsior that has been previously produced to Plaintiffs and which is silent as to exactly who is to provide materials. In addition, Brown & Root refers Plaintiffs to the documents produced by Champion to Plaintiffs in this and related litigation, and which contain various invoices evidencing that Champion directly purchased asbestos containing materials for use at the Lufkin Paper Mill. In addition, Brown & Root refers Plaintiffs to Champion's sworn discovery responses in this case wherein Champion admits to purchasing asbestos containing material, including pipe covering and transite manufactured by Johns-Manville for use at the Mill. Champion also admits to purchasing asbestos-containing packing from Southwestern Rubber & Packing Co.; Lufkin Rubber & Packing Co.; and, Cottingham, Inc. for use at the Mill.

REQUEST FOR PRODUCTION NO. 79

Please produce all documents relating to the initial construction of the Southland/Champion southern pine newsprint mill in Lufkin, Texas, including but not limited to blue prints, designs, specifications, construction contracts, bid documents, letters of intent, etc.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has previously produced to Plaintiffs all available contracts and work orders relating to work it performed at the Lufkin Paper Mill. The only Brown & Root contract that mentions asbestos is a subcontract with Excelsior that has been previously produced to Plaintiffs and which is silent as to exactly who is to provide materials. In addition, Brown & Root refers Plaintiffs to the documents produced by Champion to Plaintiffs in this and related litigation, and which contain various invoices evidencing that Champion directly purchased asbestos containing materials for use at the Lufkin Paper Mill. In addition, Brown & Root refers Plaintiffs to Champion's sworn discovery responses in this case wherein Champion admits to purchasing asbestos containing material, including pipe covering and transite manufactured by Johns-Manville for use at the Mill. Champion also admits to purchasing asbestos-containing packing from Southwestern Rubber & Packing Co.; Lufkin Rubber & Packing Co.; and, Cottingham, Inc. for use at the Mill.

REQUEST FOR PRODUCTION NO. 83

Please produce all documents evidencing violations of any regulations relating to the presence of asbestos in the workplace, including the OSHA permissible exposure limit for asbestos and the National Emission Standards for Hazardous Air Pollutants.

SUPPLEMENTAL RESPONSE: Subject to all previously filed objections, Brown & Root has already produced all OSHA and NESHAP documents relating to the Lufkin and Sheldon Paper Mills.

Respectfully submitted,

WILSON, ELSER, MOSKOWITZ, EDELMAN & DICKER

By: _____

PHILLIP S. BROWN
State Bar No. 03160300
5000 Renaissance Tower
1201 Elm Street
Dallas, Texas 75270
Telephone (214) 698-8000
Facsimile (214) 698-1101

ATTORNEYS FOR DEFENDANT, BROWN & ROOT, INC. N/K/A KELLOGG-BROWN & ROOT, INC.

CERTIFICATE OF SERVICE

This is to certify that a true and correct copy of the foregoing instrument has been forwarded to Mr. C. Andrew Waters, Waters & Kraus, 4807 Lovers Lane, Dallas, Texas, 75209, via hand delivery, and to all other counsel via first class mail on this the 31st day of January, 2000.

_____

PHILLIP S. BROWN

EXHIBIT "A"

December, 4, 1997



CURRICULUM VITAE

of

GAIL DIANE STOCKMAN

Address: 703 East Marshall Avenue, Suite 4002
Longview, Texas 75601

Telephone: 903-753-0787
Telefax: 903-757-4624

Born: July 24, 1944, Richmond, California

EDUCATION

Secondary: 1959-1962 - A.N. McCallum High School, Austin, Texas.

Undergraduate: 1962-1966 - University of Texas, Austin.
Bachelor of Arts with High Honors, 1966.
Major: Microbiology. Minor: Chemistry

Graduate: 1966-1967 - University of California, Berkeley.
Master of Arts, 1967.
Major: Bacteriology. Minor: Molecular Biology.

1968-1971 - Baylor College of Medicine, Houston, Texas.
Doctor of Philosophy, 1971.
Title of Dissertation: Cyclophosphamide-Induced Immunologic Tolerance and Immunosuppression in the Adult Mouse.
Major Professor: John J. Trentin, Ph.D.

1973-1976 - Baylor College of Medicine, Houston, Texas.
Doctor of Medicine with Honors, 1976.

Postgraduate:

1976-1979 - Baylor College of Medicine Affiliated Hospitals Internal Medicine Residency Program, Houston, Texas.

1979 - Chief Medical Resident, Veterans Administration Hospital, Baylor College of Medicine, Houston, Texas.

1980 - 1981 - Pulmonary Fellow, Department of Internal Medicine, Baylor College of Medicine, Houston, Texas.

HONORS AND AWARDS

Undergraduate:

National Merit Scholar, 1962.
Hogg Foundation Scholar, 1962.
Alpha Lambda Delta (National honorary society for women), 1963.
Junior Fellow of the College of Arts and Sciences, 1964.
Iota Sigma Pi (National honorary fraternity for women in chemistry), 1966.
Alpha Lambda Delta Highest Scholarship Award, 1966.
Phi Beta Kapa, 1966.
Bachelor of Arts with High Honors, 1966.

Graduate:

University of California Regents Fellow, 1966.
National Institutes of Health Trainee, 1968.
Alpha Omega Alpha, (National medical honor society), 1976.
Doctor of Medicine with Honors, 1976.

Postgraduate: Chief Medical Resident, Baylor College of Medicine, 1979.
Representative to the American Association of Medical Colleges Task Force on Graduate Medical Education, Washington, D.C., 1979.

Boards: American Board of Internal Medicine, 1980.

EMPLOYMENT

1971-1974 - Assistant Professor of Immunology, Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas.

1971-1974 - Assistant Immunologist and Assistant Professor of Pediatrics, Department of Pediatrics, University of Texas M.D. Anderson Hospital and Tumor Research Institute, Houston, Texas.

1981-present - Private practice of pulmonary and critical care medicine, Longview, Texas. Active member of the medical staffs of Good Shepherd Medical Center and Columbia Longview Regional Hospital.

HOSPITAL STAFF POSITIONS

Director of Pulmonary Medicine and Pulmonary Rehabilitation, Longview Regional Hospital, 1982-1985.

Chief of Medicine, Longview Regional Hospital, 1984.

Director of Pulmonary Medicine, Good Shepherd Medical Center, 1986-1992.

Medical Director, Intensive Care Unit, Good Shepherd Medical Center, 1987-1992.

Chief of Medicine, Good Shepherd Medical Center, 1991-1992.

Chairman, Medical Ethics Committee, Good Shepherd Medical Center, 1990-present.

Chairman, Quality Review and Assurance Committee, and member of the Medical Executive Committee, Columbia Longview Regional Hospital. 1997-present.

PUBLICATIONS

1. Stockman, G., and Trentin, J.J.: 1970. Induction of tolerance to horse gamma globulin and to horse-anti-mouse-thymocyte globulin using cyclophosphamide. Federation Proceedings 29: 360.

2. Stockman, G.D., Gallagher, M.T., Heim, L.R., South, M.A., and Trentin, J.J.: 1971. Differential stimulation of mouse lymphoid cells by phytohemagglutinin and pokeweed mitogen. Proceedings of the Society for Experimental Biology and Medicine 135: 980.

3. Heim, L.R., Gallagher, M.R., Stockman, G.D., South, M.A., and Trentin, J.J.: 1971. Lymphoid specificity of the "nonspecific" plant mitogens. Experimental Hematology 21: 35.

4. Stockman, G.D. and Trentin, J.J.: 1971. Cardiac allograft survival in cyclophosphamide-induced ALG-tolerant mice. Federation Proceedings 30: 601.

5. Stockman, G.D. and Trentin, J.J.: 1972. Cyclophosphamide-induced tolerance to equine gamma globulin and to equine-anti-Mouse-lymphocyte globulin in adult mice. I. Studies of antigen and drug requirements. Journal of Immunology 108: 112.

6. Stockman, G.D., Judd, K.P. and Trentin, J.J.: 1972. Cyclophosphamide-induced tolerance to equine gamma globulin and to equine-anti-mouse-lymphocyte globulin in adult mice. II. Resulting prolongation of cardiac allografts in ALG-treated animals. Transplantation 13: 66.

7. Mumford, D.M. and Stockman, G.D.: 1972. Immunological aspects of cancer in children. Cancer Bulletin 24: 5.

8. Stockman, G.D., Gillespie, D., and Mumford, D.M.: 1972. Development of a micro mixed lymphocyte culture technique using

whole blood. Federation Proceedings 31: 790.

9. Stockman, G.D., Gallagher, M.T., Heim, L.R., South, M.A., and Trentin, J.J.: 1972. Differential stimulation of mouse lymphoid cells by plant mitogens. IN: Experimental Control of Mitosis, MSS Information Corporation, New York, New York. pp 103-105.

10. Stockman, G.D., Mumford, D.M., and Wilbur, J.R.: 1972. A micro mixed leukocyte technique using whole blood. International Archives of Allergy and Applied Immunology 43: 759.

11. Stockman, G.D., Heim, L.R., South, M.A., and Trentin, J.J.: 1973. The differential effects of cyclophosphamide on the B and T cell compartments of the adult mouse. Journal of Immunology 110: 277.

12. Stockman, G.D. and Mumford, D.M.: 1974. The effect of prostaglandins on the in vitro blastogenic response of human peripheral blood lymphocytes. Experimental Hematology 2: 65.

13. Medina, D., Stockman, G.D., and Criswold, D.: 1974. The significance of chemical carcinogen-induced immunosuppression in mammary tumorigenesis in BALG/c mice. Cancer Research 34: 2663.

14. Mumford, D.M., Stockman, G.D., and Barsales, P.B.: 1975. Lymphocyte transformation studies of sea mammal blood. Experentia 31: 498.

15. Kennedy, P.S., Stockman, G.D., and Smith, F.E.: 1975. Endobronchial metastases from cervical cancer: A case report. Gynecological Oncologica 4: 340.

16. Chamberlain, W.H., Stockman, G.D., and Wray, N.P.: 1979. Shock and noncardiogenic pulmonary edema following meglumine diatrizoate for intravenous pyelography. American Journal of Medicine 67: 684.

12/4/97 DS
EXHIBIT
B

GAIL D. STOCKMAN, MD, Ph.D

Record of Testimony as an Expert Witness

1. 9-24-90 Brown, G. vs. Union Pacific Railroad
File # 1575-LM
Independent medical evaluation
Deposition

2. 11-20-92 Darby, G. and Fuller, L. vs. Union Equity
Cause # 90-01266
Evaluation based on medical records review
Deposition

3. 9-9-93 Harbour, K. vs. Shawnee Medical Center
Medical malpractice
Deposition

4. 3-7-94 Holmes, D.H., et. al. vs. U.S. Silica Co.
Cause # 89-0555. District Court, Marshall, Texas
Hearing

5. 5-9-94 Cause #371025-1719, Houston
U.S. Federal Court, Houston, Texas
State of the art with regard to asbestos-related diseases
Trial

6. 5-18-94 Bailey, Dale D. et. al. vs. Mopac, et. al.
Cause #36. 195 Anderson County, Texas
Deposition

7. 10-26-94 Cause #91-08016-K, Dallas
193rd District Court, Dallas, Texas
State of the art with regard to asbestos-related diseases
Trial

8. 1-26-95 Cause # 90-14057-H, Dallas
160th District Court, Dallas County, Texas
State of the art with regard to asbestos-related diseases
Deposition

9. 8-22-95 Cause # 90-23333, Houston
District Court, Harris County, Texas
State of the art with regard to asbestos-related diseases
Deposition

10. 10-11-95 Cause # B-911, 067-C
163rd District Court, Orange, Texas
State of the art with regard to asbestos-related diseases
Trial

11. 12-4-95 Cause #93-13951
345th District Court, Austin, Texas
State of the art with regard to asbestos-related diseases
Trial

12. 4-17-96 Donald Writesman, et.al. vs. OCF
State of the art with regard to asbestos-related diseases
Telephone deposition by David Lyle of Ness, Motley, et. al.

13. 10-17-96 Cause #17337
32nd District Court, Nolan County, Texas
Medical testimony
Trial

14. 11-22-96 Cause #94-11-6201-C
138th Judicial Court. Cameron County, Texas
State of the art with regard to asbestos-related diseases
Trial

15. 9-22-97
9-29-97 Cause #92-11238
134th Judicial Court. Dallas County, Texas
State of the art with regard to asbestos-related diseases
Trial

(Revised 08/27/99)

CURRICULUM VITAE

NAME: Philip T. Cagle

PRESENT RANK: Associate Professor

DATE & PLACE OF BIRTH: October 26, 1954
Jackson, Tennessee

NATIONALITY: United States of America

EDUCATION:

1972–76: Lambuth College, Jackson, Tennessee, Bachelor of Science, Biology

1977–81: University of Tennessee College of Medicine, Memphis, Tennessee, Doctor of Medicine

10/1980–12/1980: Medical Student Fellowship, Department of Pathology, University of Tennessee College of Medicine, Memphis, Tennessee

POSTGRADUATE TRAINING:

1981–85: Resident in Pathology, Baylor College of Medicine, Houston, Texas

1984–85: Chief Resident in Pathology, Baylor College of Medicine, Houston, Texas

1985–86: Post–Doctoral Fellow, Canadian Lung Association, University of British Columbia, Vancouver

1986–87: Parker B. Francis Fellow in Pulmonary Research, University of British Columbia, Vancouver

March, 1988: Molecular Diagnostics at the Cellular Level: Recent Biotechnical Advances, Third Annual Workshop, Tufts University School of Medicine, Boston, Massachusetts

APPOINTMENTS:

Faculty Appointments:

1984–85: Instructor, Department of Pathology, Baylor College of Medicine, Houston, Texas

1985–87:	Post–Doctoral Fellow, Department of Pathology, University of British Columbia, Vancouver
1987–92:	Assistant Professor, Department of Pathology, Baylor College of Medicine, Houston, Texas
May, 1989:	Visiting Professor, First National Pulmonary Seminar, University of Costa Rica affiliated hospitals, San Jose, as guest of the Caja Costarricensede Seguro Social Centro Nacional de Docencia E Investigacion en Salud y Seguridad Social, Asociacion Costarricense de Neumologia and Colegio de Médicos y Cirujano
1992–93:	Assistant Professor, Department of Medicine, Baylor College of Medicine, Houston, Texas
1993–pr:	Associate Professor, Department of Pathology, Baylor College of Medicine, Houston, Texas
1993–pr:	Associate Professor, Department of Medicine, Baylor College of Medicine, Houston, Texas
April, 1995:	Visiting Professor, University of Massachusetts Medical Center, Worcester, Massachusetts
June, 1995:	Visiting Professor, Evangelismos Hospital, Athens, Greece
May, 1998:	Visiting Professor, University of British Columbia, Vancouver Hospital and Health Sciences Center, Vancouver, British Columbia, Canada

Hospital Appointments:

1987–pr:	Attending Pathologist, The Methodist Hospital, Houston, Texas
1987–pr:	Attending Pathologist, Harris County Hospital District, Houston, Texas

Other Appointments:

1983–84:	Resident Assistant Medical Examiner, Harris County Medical Examiner's Office, Houston, Texas
1987–93:	Director, Pulmonary Research Laboratory of the Department of Pathology, Baylor College of Medicine, Houston, Texas
1988–90:	Director, Pulmonary Pathology Course, Houston Community College, Respiratory Therapist RTT 2206, Houston, Texas
1993–pr:	Director, Center for Pulmonary Pathology, Baylor College of Medicine, Houston, Texas
1993:	Scientific Seminar Chairman, Houston Society of Clinical Pathologists
1993–97:	Cancer Section, Steering Committee of the American College of Chest Physicians
1994–95:	Membership Committee, Texas Society of Pathologists
1994–pr:	United States and Canadian Mesothelioma Reference Panel
1995:	Committee on Working Formulation of Nomenclature in Diagnosis of Lung Transplant Rejection
1995-1997	Medical Director, Histology Laboratory, Department of Pathology, Baylor College of Medicine
1995-pr:	Education Committee, Pulmonary Pathology Society
1997-pr	Chairman, Awards Committee, Pulmonary Pathology Society
1998-pr	International Mesothelioma Workshop Committee

SPECIALTY CERTIFICATION: American Board of Pathology for Anatomic and Clinical Pathology, 1985

MEDICAL LICENSES:

1981: Tennessee (# M.D. 13670)
1983: Texas (# G 4092)

HONORS & AWARDS:

1979: Israel D. Michelson Scholarship Award in Pathology and Micro–biology, University of Tennessee College of Medicine

1981: Scholastic Achievement Award, University of Tennessee College of Medicine

Research:

1984–85: American Cancer Society, Texas Division, Fellowship – "An Immunofluorescent Study of Collagen Subtypes in Pulmonary Scar Cancers"

1991: Nominee for the Virginia and Ernest Cockrell, Jr. Award for Research, The Methodist Hospital Foundation, "The Utility of *myc* Oncogenes in Predicting Biologic Behavior of Non–Small Cell Lung Cancers"

1992: Nominee for the Virginia and Ernest Cockrell, Jr. Award for Research, The Methodist Hospital Foundation, "The Utility of *myc* Oncogenes in Predicting Biologic Behavior of Non–Small Cell Lung Cancers"

1992: Alfred Soffer Research Award, American College of Chest Physicians, "Bronchial Neuroendocrine Cells in Primary Pulmonary Hypertension" (58th Annual Scientific Assembly Chicago, Oct. 29, 1992)

INSTITUTION ACTIVITIES:

1983–84: Vice–President, Baylor Housestaff Association

1983–84: Housestaff member, Graduate Medical Education Committee, Baylor College of Medicine

1983–84: Housestaff member, Recruitment and Residency Affairs Subcommittee, Baylor College of Medicine

1987–92: Safety Committee, Physician Representative, Department of Pathology, The Methodist Hospital

1989–pr: Residency Committee, Department of Pathology, Baylor College of Medicine

1990–pr: Associate Director, Residency Program, Department of Pathology, Baylor College of Medicine

1990–pr: Chairperson, Lung Cancer Work Group, Cancer Committee, The Methodist Hospital

1990–pr: Cancer Registry Subcommittee, The Methodist Hospital

GRANTS:

Biomedical Research Support Grant 510–G15900, Proj. No.: P014, "The Influence of Estrogens on Pulmonary Adenocarcinoma," P.I. – Philip T. Cagle, M.D., Co–Investigator – Mary R. Schwartz, M.D., January 1, 1989 – March 31, 1990, $15,000.00

The Moran Foundation, "The Influence of Glucocorticoids on Pulmonary Adenocarcinoma," P.I. – Philip T. Cagle, M.D., January 1, 1989 – December 31, 1989, $5,689.00

The Methodist Hospital Foundation, "The Utility of *myc* Oncogenes in Predicting Biologic Behavior of Non– Small Cell Lung Cancers," P.I. – Philip T. Cagle, M.D., January 1, 1990 – December 31, 1991, $28,144.00

American Lung Association, "Estrogen and Progesterone Receptor Genes in Non–Small Cell Lung Cancer," P.I. – Philip T. Cagle, M.D., July 1, 1990 – June 30, 1991, $4,153.69

OTHER RESEARCH PROTOCOLS:

Medical Hematology, The Methodist Hospital/Baylor College of Medicine, Reference Protocol H3415. Isolation, Culture and Cytokine Expansion of Tumor Infiltrating Lymphocytes in Patients with Non-Small Cell Carcinoma of the Lung Undergoing Primary Excision. P.I. - Philip McCarthy, M.D.; Associate Investigator, Philip T. Cagle, M.D. In-house funding, 1995-pr.

PROFESSIONAL ORGANIZATIONS:

Local and State:	Harris County Medical Society Texas Medical Association Houston Society of Clinical Pathologists Texas Society of Pathologists Texas Society of Cytology
National and International:	American College of Chest Physicians American Association of Pathologists American Thoracic Society U.S.–Canadian Academy of Pathology Pulmonary Pathology Society American Association for the Advancement of Science Federation of American Societies for Experimental Biology PRODS, Association of Pathology Chairmen American College of Physician Executives American Medical Association
Manuscript Reviewer, Ad hoc:	American Journal of Respiratory Cell and Molecular Biology American Journal of Respiratory and Critical Care Medicine American Journal of Pathology Archives of Pathology and Laboratory Medicine Cancer Cancer Research Chest Journal of the Cleveland Clinic Mayo Clinic Proceedings

ORIGINAL RESEARCH PEER-REVIEWED PUBLICATIONS:

1. **Cagle PT**, Mace JL, Judge DM, Teague RB, Wilson RK, Greenberg SD. Pulmonary melanoma: Primary versus metastatic. *Chest* 85:125–126, 1984.

2. **Cagle PT**, Langston C. Pulmonary veno–occlusive disease as a cause of sudden infant death. *Arch Pathol Lab Med* 108:338–340, 1984.

3. **Cagle PT**, McGavran M, Lane M, Greenberg SD. Small cell carcinoma of the lung treated with irradiation and chemotherapy. *Chest* 85:439–440, 1984.

4. Miller RH, **Cagle PT**, Pitcock JK, McGavran M. Laryngeal atresia: A detailed histologic study. *Int J Pediatr Otorhinolaryngol* 7:273–280, 1984.

5. **Cagle PT**, Kim HS, Titus JL. Congenital stenotic arteriopathy with medial dysplasia. *Human Pathology* 16:528–530, 1985.

6. **Cagle PT**, Cohle SD, Greenberg SD. Natural history of pulmonary scar cancer: Clinical and pathologic implications. *Cancer* 56:2031–2035, 1985.

7. **Cagle PT**, Hough AJ, Pysher TJ, Page DL, Johnson EH, Kirkland RT, Holcombe JH, Hawkins EP. Comparison of adrenal cortical tumors in children and adults. *Cancer* 57:2235–2237, 1986.

8. **Cagle PT**, Hurst D, Saleem A. Substitution of biochemical urine screening for routine urine microscopy. *Texas Medicine* 82:41–42, 1986.

9. **Cagle PT**, Ferry GD, Beaudet AL, Hawkins EP. Pulmonary hypertension in an 18 year old girl with Cholesterol Ester Storage Disease (CESD). *Am J Med Genet* 24:711–722, 1986.

10. Heckman CJ, Truong LD, **Cagle PT**, Font RL. Pulmonary blastoma with rhabdo–myosarcomatous differentiation: An electron microscopic and immunohistochemical study. *Am J Surg Path* 12:35–40, 1988.

11. Berean K, Truong LD, Dudley AW, **Cagle PT**. Immunohistochemical characterization of pulmonary blastoma. *Am J Clin Pathol* 89:773–777, 1988.

12. **Cagle PT**, Langston C, Thurlbeck WM. The effect of age on post–pneumonectomy growth in rabbits. *Pediatric Pulmonology* 5:92–95, 1988.

13. **Cagle PT**, Mattioli CA, Truong LD, Greenberg SD. Immunohistochemical diagnosis of pulmonary eosinophilic granuloma on lung biopsy. *Chest* 94:1133–1137, 1988.

14. **Cagle PT**, Truong LD, Holland VA, Lawrence EC, Rogers BB, Schwartz MR, Kolda T, Buffone GJ, Noon GP, Greenberg SD. Factors contributing to mortality in lung transplant recipients: An autopsy study. *Mod Pathol* 2:85–89, 1989.

15. Saito K, **Cagle PT**, Berend N, Thurlbeck WM. The "Destructive Index" in non–emphysematous and emphysematous lungs: Morphologic observations and correlation with function. *Am Rev Respir Dis* 139:308–312, 1989.

16. **Cagle PT**, Truong LD, Holland VA, Lawrence EC, Noon GP, Greenberg SD. Lung biopsy evaluation of acute rejection versus opportunistic infection in lung transplant patients. *Transplantation* 47:713–715, 1989.

17. Truong LD, Mawad J, **Cagle PT**, Mattioli CA. Cytoplasmic crystals in multiple myeloma associated fanconi syndrome: A morphologic study including immunoelectron microscopy. *Arch Pathol Lab Med* 113:781–785, 1989.

18. **Cagle PT**, Taylor LD, Schwartz MR, Ramzy I, Elder F. Cytogenetic abnormalities common to adenocarcinoma metastatic to the pleura. *Cancer Genet Cytogenet* 39:219– 225, 1989.

19. **Cagle PT**, Truong LD, Roggli VL, Greenberg SD. Immunohistochemical differentiation of sarcomatous mesotheliomas from other spindle cell neoplasms. *Am J Clin Pathol* 92:566–571, 1989.

20. Truong LD, Mody DR, **Cagle PT**, Jackson–York G, Schwartz MR, Wheeler TM. Thymic carcinoma: A clinicopathologic study of 13 cases. *Am J Surg Path* 14:151–166, 1990.

21. Truong LD, Rangdaeng S, **Cagle PT**, Ro J, Hawkins H, Font RL. The diagnostic utility of desmin: A study of 584 cases and review of the literature. *Am J Clin Pathol* 93:305– 314, 1990.

22. **Cagle PT**, Langston C, Goodman JC, Thurlbeck WM. Autoradiographic assessment of cellular proliferation in post–pneumonectomy lung growth. *Am J Resp Cell Mol Biol* 3:153–158, 1990.

23. **Cagle PT**, Mody DR, Schwartz MR. Estrogen and progesterone receptors in bronchogenic carcinoma. *Cancer Research* 50:6632–6635, 1990.

24. Holland VA, **Cagle PT**, Windsor NT, Noon GP, Greenberg SD, Lawrence EC. Lymphocyte subset populations in bronchiolitis obliterans after heart–lung transplantation. *Transplantation* 50:955–959, 1990.

25. Truong L, Maccato ML, Awalt H, **Cagle PT**, Schwartz M, Kaplan A. Serous surface carcinoma of the peritoneum: A study of 22 cases. *Human Pathology* 21:99–110, 1990.

26. Xu HJ, Hu SH, **Cagle PT**, Moore GE and Benedict WF. Absence of retinoblastoma protein expression in primary non–small cell lung carcinomas. *Cancer Research* 51:2735–2739, 1991.

27. Abu–Farsakh H, **Cagle PT**, Buffone GJ, Bruner JM, Weilbaecher D and Greenberg SD. Heart allograft involvement with Epstein–Barr virus–associated post–transplant lymphoproliferative disorder. *Arch Pathol Lab Med* 116:93–95, 1992.

28. Cagle PT, Buffone GJ, Holland VA, Samo TC, Demmler, GJ, Noon GP and Lawrence EC. Semiquantitative measurement of cytomegalovirus DNA in lung and heart–lung transplant patients by *in vitro* DNA amplification. *Chest* 101:93–96, 1992.

29. Cagle PT, Alpert LC and Carmona PA. Peripheral biphasic adenocarcinoma of the lung: Light microscopic and immunohistochemical findings. *Hum Pathol* 23:197–200, 1992.

30. Cagle PT, Langston C, Fraire AE, Roggli VL and Greenberg SD. Absence of correlation between nuclear morphometry and survival in Stage I non–small cell lung cancers. *Cancer* 69:2454–2457, 1992.

31. Fordice J, Katras T, Jackson RE, Cagle PT, Jackson D, Zaleski H, Asimacopoulos J. Massive splenomegaly in sarcoidosis. *S J Med* 85:775–778, 1992.

32. Cagle PT, Kovac M, Ramzy I. Causes of false results in transthoracic fine–needle lung aspirates. *ACTA Cytologica* 37:16–20,1993.

33. Frost AE, Keller CA, Cagle PT. The multi–organ transplant group. Severe ischemic injury to the proximal airway following lung transplantation: Immediate and long–term effects on bronchial cartilage. *Chest* 103:1899–1901, 1993.

34. Cagle PT, Wessels R, Greenberg SD. Concurrent mesothelioma and adenocarcinoma of the lung in a patient with asbestosis. *Mod Pathol* 6:438–441, 1993.

35. Subramanian D, Albrecht S, Gonzalez JM, Cagle PT. Primary pulmonary lymphoma: Diagnosis by immunoglobulin gene rearrangement study using a novel polymerase chain reaction technique. *Am Rev Respir Dis* 148:222–226, 1993.

36. Buffone GJ, Frost A, Samo T, Demmler GJ, Cagle PT, Lawrence EC. The diagnosis of CMV pneumonitis in lung and heart/lung transplant patients by PCR compared with traditional laboratory criteria. *Transplantation* 56:342–347, 1993.

37. Frost AE, Kellar CA, Brown RW, Noon GP, Short HD, Abraham JL, Pacinda S, Cagle PT. Giant cell interstitial pneumonitis: Disease recurrence in the transplanted lung. *Am Rev Respir Dis* 148:1401–1404, 1993.

38. Bailey ME, Fraire AE, Greenberg SD, Barnard J, Cagle PT. Pulmonary histopathology in cocaine abusers *Human Pathology* 25:203–207, 1994.

39. Hicks MJ, Flaitz CM, Wong MEK, McDaniel RK, Cagle PT. Clear cell variant of calcifying epithelial odontogenic tumor: case report and review of the literature. *Head and Neck* 16:272–277, 1994.

40. Cagle PT, Brown RW, Lebovitz RM. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. *Human Pathology* 25:443–448, 1994.

41. Younes M, Lebovitz RM, Bommer KE, Cagle PT, Morton D, Khan S, Laucirica R. p53 accumulation in benign breast biopsies. *Human Pathology* 26:155-158, 1995.

42. Cagle PT, Brown RW, Frost A, Kellar CA, Yousem SA. Diagnosis of chronic lung transplant rejection by transbronchial biopsy. *Mod Pathol* 8:137-142, 1995.

43. Ledet SC, Brown RW, Cagle PT. p53 immunostaining in the differentiation of inflammatory pseudotumor from sarcoma involving the lung. *Mod Pathol* 8:282-286, 1995.

44. Frost AE, Keller CA, Noon GP, Short HD, Cagle PT. Outcome of the native lung following single lung transplant. *Chest* 107:981-984, 1995.

45. Keller CA, Cagle PT, Brown RW, Noon GP, Frost AE. Bronchiolitis obliterans in recipients of single, double and heart–lung transplantation. *Chest* 107:973-980, 1995.

46. Keller CA, Frost A, Cagle PT, Abraham JL. Pulmonary alveolar proteinosis in a painter with elevated pulmonary concentrations of titanium: Report of a case and proposition of an hypothesis in the pathogenesis of the disease. *Chest* 108:277-280, 1995.

47. Yousem SA, Berry GJ, Cagle PT, Chamberlain D, Husain A, Hruban RH, Marchevsky A, Ohori P, Ritter J, Stewart S, Tazelaar HD. A revision of the 1990 working formulation for the classification of lung allograft rejection. Jrnl Heart & Lung Transplantation 15:1-15, 1996.

48. Conway EJ, Hudnall D, Lazarides A, Bahler A, Fraire AE, Cagle PT. Absence of evidence for an etiologic role for Epstein-Barr virus in neoplasms of the lung and pleura. Modern Pathol 9(5):491-495, 1996.

49. Pacinda SJ, Ledet SC, Langston C, Gondo MM, Brown RW, Carmona PA, Franklin R, Roggli VL, Cagle PT. p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas. Human Pathology 27(6):542-546, 1996.

50. Xu H-J, Cagle PT, Hu S-X, Li J, Benedict WF. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: Potential synergistic effects on prognosis. Clin Can Res 2:1169-1176, 1996.

51. Frost AE, Jammal CT, Cagle PT. Hyperacute rejection following lung transplantation. Chest 110:559-562, 1996.

52. Mullick SS, Ramzy I, Brown RW, Smith D, Gondo MM, Green LK, Cagle PT. p53 gene product in pleural effusions: Practical use in distinguishing from malignant cells. Acta Cytologica 40(5):855-860, 1996.

53. Cagle PT, Fraire AE, Greenberg SD, Cox A, Brown RW. Potential utility of p53 immunopositivity in differentiation of adenocarcinomas from reactive epithelial atypias of the lung. Human Pathology 27:1198-1203, 1996.

54. Bailey ME, Brown RW, Mody DR, **Cagle PT**, Ramzy I. BER-EP4 differentiates adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions: A comparison with CEA, B72.3 and Leu M-1. Acta Cytologica 40(6):1212-1216, 1996.

55. Yi ES, Harclerode D, Gondo M, Stephenson M, Brown RW, Younes M, **Cagle PT**. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. *Mod Pathol* 10(2):142-148, 1997.

56. Brown RW, Campagna LB, Dunn JK, **Cagle PT**. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma: A diagnostic adjunct in the determination of primary site. *American Journal of Clinical Pathology* 107:12-19, 1997.

57. **Cagle PT**, El Naggar AK, Xu H-J, Hu S-X, Benedict WF. Differential retinoblastoma protein expression in neuroendocrine tumors of the lung : Potential diagnostic implications. *The American Journal of Pathology* 150:393-400, 1997.

58. Younes M, Brown RW, Stephenson M, Gondo M, **Cagle PT**. Overexpression of Glutl and Glut3 in stage I non-small cell carcinoma is associated with poor survival. *Cancer* (80)6:1046-1051, 1997

59. Anton RC, Brown RW, Younes M, Gondo MM, Stephenson MA, **Cagle PT**. Absence of prognostic significance of bcl-2 immunopositivity in non-small cell lung cancer: Analysis of 427 cases. *Human Pathology*.28:1079-1082, 1997.

60. Marchevsky AM, Patel S, Wiley KJ, Stephenson MA, Gondo M, Brown R, Yi ES, Benedict WF, Anton RC, **Cagle PT**. Artificial neural networks and logistic regression as tools for prediction of survival in patients with Stages I and II non-small cell lung cancer. *Mod Pathol* 11(7): 618-625, 1998.

61. Mangano WE, **Cagle PT**, Churg A, Vollmer RT, Roggli VL. The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining. *Am J Clin Pathol* 110(2):191-199, 1998.

62. Anton R, Schwartz MR, Kessler M, **Cagle PT**. Metastatic carcinoma of the prostate mimicking primary carcinoid tumor of the lung and mediastinum. *Pathology Research and Practice* 194(11):753-8, 1998.

63. Wang S, **Cagle PT**, Rooney L, Stephenson MA, Seaver SJ, Fraire AE. Zonal Distribution of mast cells in bronchiolitis obliterans and interstitial pulmonary fibrosis. *Applied Immunohistochemistry* 6(4):214-218, 1998.

64. Khoor A, Whitsett JA, Stahlman MT, Olson SJ, **Cagle PT**. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. *Hum Pathol* 30(6):695-700, 1999.

65. Lopez-Terrada D, Bloom MGK, Cagle PT, Ostrowski ML. Oncocytic mucoepidermoid carcinoma of the trachea. *Arch Pathol Lab Med* 123(7):635-637, 1999.

66. Alvarez JL, Gonzalez JM, Cagle PT, Cartwright J, Jones PH. Skin nodules, pulmonary nodules and a history of asthma. Chest (in press)

67. Yi ES, Colby TV, Cagle PT, Gondo M, Stephenson M, Harclerode D. Alveolar macrophages express intercellular adhesion molecule-1 (ICAM-1) in hypersensitivity pneumonitis. (in press)

68. Dosake-Akita H, Cagle PT, Hiroumi H, Fujita M, Kawakami, Benedict WF. Retinoblastoma (RB) and $p16^{INK4}$ protein expression in large cell neuroendocrine carcinomas and small cell carcinomas of the lung. *Cancer* (in press)

69. Klemen H, Husain AN, Cagle PT, Garrity ER, Popper HH. Recurrent sarcoidosis in the transplanted lung – does it exist? A PCR based study on four cases. Virchows Archiv (in press)

70. Fraire AE, Klemen H, Mikesell SL, Popper HH, Baker S, Cagle PT. Platelet derived growth factors A and B in bronchiolitis obliterans organizing pneumonia and constricting bronchiolitis obliterans. (in press)

71. Kadmon D, Smith C, Ayala G, Sharma A, Cagle PT. Solitary pulmonary metastasis from prostate cancer. Journal of Urology (in press)

72. Ledet S, Hoefler G, Conway J, Winter E, Hudnall D, Wöeckel W, Cagle PT, Popper HH. Detection of Epstein–Barr virus in inflammatory pseudotumor of the lung by polymerase chain reaction and in–situ hybridization. (submitted)

73. Rubin R, Cagle PT, Sessoms SL. Occurrence of rheumatoid lung after bone marrow transplantation (submitted).

74. Cagle PT, Langston C, Thurlbeck WM. A morphometric study of normal lung growth in New Zealand white rabbits (submitted).

75. Keller CA, Frost A, Cagle PT, Eschenbacher W. Hair spray lung: Hypersensitivity pneumonitis in a hair dresser (Thesaurosis) (submitted)

76. Adachi R, Hale KA, Cagle PT. Unusual clinical and histologic presentation of intraparenchymal pulmonary papilloma. (submitted).

77. Ostrowski ML, Brown RW, Lebovitz RM, Chakraborty S, Cox A, Stephenson M, Cagle PT. p53 protein in 406 endobronchial biopsies: Correlation of expression in preinvasive lesions with clinical outcome. (submitted).

78. Maisch SA, Brown RW, Gondo M, Stephenson M, **Cagle PT**. Rb expression in preinvasive and invasive squamous lesions of the bronchus: Immunohistochemical evaluation of 312 endobronchial biopsies (submitted)

79. Euscher ED, Anton RC, Coffey DM, Wiley KJ, Stephenson MA, Gondo MM, Genty CE, Truong LD, Espada R, **Cagle PT**. Connective tissue remodeling in emphysema: platelet derived growth factor and tenascin in 123 bullectomy specimens (submitted)

80. **Cagle PT**, Fraire AE, Greenberg SD, Rajagopalan S. K-*ras* codon 12 mutations in the pathogenesis of adenocarcinomas associated with atypical epithelium of interstitial pulmonary fibrosis. (in preparation)

81. Bommer B, Rajagopalan S, Greenberg SD, Fraire AE, **Cagle PT**. K-*ras* codon 12 mutations in pulmonary mucinous cystic tumor and bronchioloalveolar carcinoma: A possible pathogenic relationship. (in preparation)

BOOKS

1. **Cagle PT** (editor). Diagnostic Pulmonary Pathology. Marcel Dekker (in press).

2. Bedrossian C, **Cagle PT**, Luna M, Davila, Greenberg SD. Pulmonary Pathology: An Integrated Text and Atlas. Lippincott-Raven. (in preparation)

INVITED REVIEWS AND BOOK CHAPTERS:

1. **Cagle PT**, Thurlbeck WM. State of the Art: Post–pneumonectomy compensatory growth. *Am Rev Respir Dis* 138:1314–1326, 1988.

2. **Cagle PT**. The Cytogenetics and Molecular Genetics of Lung Cancer: Implications for Pathologists. In: *Pathology Annual*, Rosen PP and Fechner RE, editors, Vol. 25, Part 2, p. 317–329. Appleton & Lange, Inc., E. Norwalk, 1990.

3. **Cagle PT**. Pulmonary pathology in lung transplant patients. In: *Progress in Surgical Pathology*, Fenoglio–Preiser CM, Wolff M and Rilke F, editors, pp. 151–166, Field and Wood, New York, 1992.

4. Wright JL, **Cagle P**, Churg A, Colby TV, and Myers J. Diseases of the small airways. *Am Rev Respir Dis* 146:240–262, 1992.

5. **Cagle PT**. Scientific Report: New Trends in Lung Cancer. The Methodist Hospital Cancer Program Annual Report, Methodist Cancer Program, Houston, pp. 20-23, 1993.

6. **Cagle PT**. Molecular Pathology of Lung Cancer and Its Clinical Relevance. In: *Current Topics in Pulmonary Pathology*, Katzenstein A–L, Churg A, editors, USCAP Monographs, 36:134-44, 1993.

7. Cagle PT. Non–specific ("Usual") Interstitial Pneumonia, Interstitial Fibrosis and the Honeycomb Lung. In: *Pathology of Pulmonary Disease*, Saldana M, editor, pp. 325– 339, J.B. Lippincott, Philadelphia, 1994.

8. Cagle PT. Chronic Interstitial Pneumonia With Specific Histologic Features. In: *Pathology of Pulmonary Disease*, Saldana M, editor, pp. 341–355, J.B. Lippincott, Philadelphia, 1994.

9. Cagle PT. Update on New Trends in Lung Cancer. The Methodist Hospital Cancer Program Annual Report, Methodist Cancer Program, p. 22, Houston, 1994.

10. Cagle PT. Tumors of the Lung (Excluding Lymphoid Tumors). In *Pathology of the Lung*, 2nd ed., Thurlbeck WM, Churg AM, editors, pp. 437–551, Thieme Medical Publishers:New York, 1995.

11. Cagle PT. Lung Transplant Pathology. In: *Pathology of the Lung*, 2nd ed., Thurlbeck WM, Churg AM, editors, pp 827–849, Thieme Medical Publishers:New York, 1995.

12. Cagle PT, Lega M. Pathogenesis/Pathology of Graft Dysfunction. In *Primer on Transplantation*, D.J. Norman, W.N. Suki, editors, pp. 527-537, The American Society of Transplant Physicians, Thorofare, NJ, 1998.

13. Cagle PT. Differential diagnosis between primary and metastatic caricnomas. In: *Lung Tumors: Fundamental Biology and Clinical Management*, C. Brambilla, E. Brambilla, editors, pp. 127-137, Marcel Dekker, New York, NY, 1999.

14. DeRemee RA, Anton RC, Cagle PT. Pulmonary Angiitis and Granulomatosis in *The Granulomatous Disorders*, James DG and Zumla A, editors, Cambridge University Press, 1999.

15. Cagle PT. Lung Cancer in *Molecular Biology in Cancer Medicine*, Kurzrock R and Talpaz M, editors, pp. 367-378, Martin Dunitz, Ltd., London, UK, 1999.

16. Cagle PT. Endobronchial and Transbronchial Biopsies in *Diagnostic Dilemmas in Pulmonary Pathology*, Cagle PT, editor, Marcel Dekker (in press)

17. Anton R, Cagle PT. Intracellular and Extracellular Structures in *Diagnostic Dilemmas in Pulmonary Pathology*, Cagle PT, editor, Marcel Dekker (in press)

18. Seaver SJ, Cagle PT. Molecular Pathology of the Lung in *Diagnostic Pulmonary Pathology*, Cagle PT, editor, Marcel Dekker. (in press)

19. Galateau-Sallé F, Cagle PT. Non-malignant Versus Malignant Proliferations on Pleural Biopsy in *Diagnostic Diagnostic Pulmonary Pathology*, Cagle PT, editor, Marcel Dekker (in press).

PLATFORM PRESENTATIONS:

1. Cagle PT, Greenberg SD, Cohle SD. Natural History of Pulmonary Scar Cancers. International Academy of Pathology, U.S.–Canadian Division Annual Meeting, San Francisco, CA. March, 1984.

2. Cagle PT, Hawkins EP, Kirkland RT, Pysner TJ, Holcombe JH, Hough AJ, Page DL. Prognostic Criteria of Adrenal Cortical Neoplasms in Children. Pediatric Pathology Society Annual Meeting, San Francisco, CA. March, 1984.

3. Cagle PT, Truong LD, Holland VA, Lawrence EC, Greenberg SD. Biopsy and autopsy evaluation of acute rejection versus infection in transplanted lungs. U.S.–Canadian Academy of Pathology Annual Meeting, Washington, D.C., March, 1988.

4. Cagle PT, Truong LD, Roggli VL, Greenberg SD. Immunohistochemical differentiation between sarcomatous mesotheliomas and other spindle–cell neoplasms. American Thoracic Society Annual Meeting, Las Vegas, Nevada, May, 1988.

5. Cagle PT, Truong LD, Holland VA, Lawrence EC, Greenberg SD. Clinical utility of lung biopsy in the management of lung transplant patients. American Thoracic Society Annual Meeting, Las Vegas, Nevada, May, 1988.

6. Cagle PT, Thurlbeck WM. Autoradiographic assessment of the sequence of cellular proliferation in post–pneumonectomy lung growth. American Thoracic Society Annual Meeting, Las Vegas, Nevada, May, 1988.

7. Cagle PT, Truong LD, Holland VA, Lawrence EC, Greenberg SD. Histopathologic evaluation of pulmonary infection in lung transplant patients. 31st Aspen Lung Conference, Aspen, Colorado, June, 1988.

8. Cagle PT, Truong LD, Holland VA, Lawrence EC, Greenberg SD. Immunohistochemical characterization of lymphocytes in post–transplant obliterative bronchiolitis. 54th Annual Scientific Assembly of the American College of Chest Physicians, Anaheim, California, October, 1988.

9. Cagle PT, Holland VA, Samo TC, Buffone GJ, Noon GP, Lawrence EC. Early detection of cytomegalovirus pulmonary infection in a heart–lung transplant patient by polymerase chain reaction amplification. U.S.–Canadian Academy of Pathology Annual Meeting, Boston, Massachusetts, March, 1990.

10. Cagle PT, Langston C, Weilbaecher D, Frost AE, Keller CA, Bayardo RJ. Bronchial neuroendocrine cells in primary pulmonary hypertension. American College of Chest Physicians 58th Annual Scientific Assembly, October, 1992, Chicago, Illinois.

11. Keller CA, Frost AE, **Cagle PT**, Young J, Lawrence C, Noon G. Diagnosis and incidence of bronchiolitis obliterans following single, double and heart–lung transplantation. American College of Chest Physicians 58th Annual Scientific Assembly, October, 1992, Chicago, Illinois.

12. Brown RW, Fraire AE, Roggli V, **Cagle PT**. Assessment of proliferative fraction by PCNA in stage I non–small cell lung cancer. United States and Canadian Academy of Pathology, March, 1993, New Orleans.

13. Mullick SS, Ramzy I, Brown RW, Smith D, Gondo MM, Green LK, **Cagle PT**. Immuno reactive localization of the p53 product in pleural effusions: practical use in distinguishing benign from malignant cells. Texas Society of Pathology Annual Meeting, El Paso, Texas, January 27, 1995.

14. **Cagle PT**, Fraire AE, Greenberg SD, Rajagopalan S. K–*ras* codon 12 mutations in the pathogenesis of adenocarcinomas associated with atypical epithelium of interstitial pulmonary fibrosis. United States and Canadian Academy of Pathology 84th Annual Meeting, Toronto, Ontario, March 14, 1995.

15. Campagna LB, Dunn JK, **Cagle PT**, Brown RW. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma: A diagnostic adjunct in the determination of primary site. American Society of Clinical Pathologists Spring National Meeting Scientific Sessions, Orlando, Florida, April 24,1995.

16. Hite W, Masciangelo T, Martin AA, **Cagle PT**. Anterior mediastinal mass presenting as a chronic cough with normal chest reontgenogram. Southern Medical Association Annual Meeting, Kansas City, MO, November, 1995

17. Anton RC, Brown RW, Younes M, Gondo M, Stephenson M, **Cagle PT**. Absence of prognostic significance of bcl-2 immunopositivity in non-small cell lung cancer: Analysis of 427 cases. Texas Society of Pathology Annual Meeting, Dallas, Texas, February 2, 1996.

18. **Cagle PT**, Frost AE, Stephenson M, Gondo M, Truong LD. Tenascin expression in constrictive bronchiolitis of chronic lung transplant rejection versus bronchiolitis obliterans-organizing pneumonia. United States and Canadian Academy of Pathology 85th Annual Meeting, Washington, D.C., March 26, 1996.

19. Maisch SA, Brown RW, Gondo M, Stephenson M, **Cagle PT**. Rb expression in preinvasive and invasive squamous lesions of the bronchus: Immunohistochemical evaluation of 312 endobronchial biopsies. United States and Canadian Academy of Pathology 85th Annual Meeting, Washington, D.C., March 25, 1996.

20. Yi ES, Harclerode D, Brown RW, Younes M, Gondo M, Stephenson M, **Cagle PT**. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. United States and Canadian Academy of Pathology 85th Annual Meeting, Washington, D.C., March 25, 1996.

21. Yi ES, Colby TV, **Cagle PT**, Gondo M, Stephenson M, Harclerode D. Alveolar macrophages express intercellular adhesion molecule-1 (ICAM-1) in hypersensitivity pneumonitis. United States and Canadian Academy of Pathology 85th Annual Meeting, Washington, D.C., March 26, 1996.

22. Fraire AE, Klemen H, Mikesell S, Popper HH, **Cagle PT**. Platelet derived growth factor in bronchiolitis obliterans-organizing pneumonia. United States and Canadian Academy of Pathology 85th Annual Meeting, Washington, D.C., March 26, 1996.

23. Anton RC, Coffey DM, Gondo M, Stephenson MA, Brown RW, Lebovitz RM, **Cagle PT**. Expression of cyclins D1 and E independently predict prognosis in squamous cell carcinoma of the lung. Texas Society of Pathologists Annual Meeting, Corpus Christi, Texas, January 31, 1997.

24. Coffey DM, Castro CY, Gondo MM, Stephenson MA, Brown RW, Lebovitz RM, **Cagle PT**. p16 expression and survival in non-small cell lung cancer: analysis of 414 cases. United States-Canadian Academy of Pathology, 86th Annual Meeting, Orlando, Florida, March 4, 1997.

25. Anton RC, Brown RW, Gondo MM, Stephenson MA, **Cagle PT**. Correlation of alpha-feto-protein receptor expression to advancing stage and grade of non-small cell lung cancer. American Society for Investigative Pathology (Federation of American Societies for Experimental Biology) Experimental Biology '97. Minisymposium on *Molecular Markers of Cancer* New Orleans, Louisiana, April 7, 1997.

26. Castro CY, Wiley KJ, Carlson NR, Gondo MM, **Cagle PT**. Comparison of demographics and cell cycle regulators in bronchioloalveolar carcinomas and solid/acinar adenocarcinomas versus mixed pattern adenocarcinomas.). United States-Canadian Academy of Pathology, 87th Annual Meeting, March 3, 1998.

27. Cai YC, Rogglie VL, Mark E, Xu X, **Cagle PT**, Seaver S, Savas L, Fraire AE. Epidermal growth factor receptor in reactive mesothelial proliferations, epithelial malignant mesothelioma and carcinoma of lung: A study of 114 cases. United States and Canadian Academy of Pathology 88th Annual Meeting, San Francisco, CA, March 20-26, 1999.

28. Sharma A, Rodriguez M, Truong, LT, **Cagle PT**. Utility of calretinin and HBME-1 immunostaining in differentiating metastatic renal cell carcinoma from malignant mesotheliomas: An immunohistochemical study. Federation for the Advancement of Science and Experimental Biology '99, Washington, DC, April 18, 1999.

29. Zemrus TL, Anton RC, Barrios R, Habib G, Seaver SJ, Wiley KJ, Gondo MM, Carlson NR, King MS, **Cagle PT**. Expression of SV40 large T antigen (Tag) in 141 human malignant mesotheliomas (MM): A possible etiologic role? Federation for the Advancement of Science and Experimental Biology '98, San Francisco, CA, April 19, 1998.

BSTRACTS:

1. Cagle PT, Greenberg SD, Cohle SD. Natural History of Pulmonary Scar Cancers. *Lab Invest* 50:8A–9A, 1984.

2. Cagle PT, Hawkins EP, Kirkland RT, Pysner TJ, Holcombe JH, Hough AJ, Page DL. Prognostic Criteria of Adrenal Cortical Neoplasms in Children. *Lab Invest* 50:2P, 1984.

3. Cagle PT, McFadden D, McGee F, Truong, L, Dudley A, Thurlbeck WM. An Immunohistochemical Study of the Histogenesis of Pulmonary Blastoma. *Lab Invest* 56:9A, 1987.

4. Cagle PT, Thurlbeck WM. The Effect of Age on the Post–pneumonectomy Adaptive Response in Rabbits. *Am Rev Res Dis* 135:A24, 1987.

5. Cagle PT, Truong LD, Holland VA, Lawrence EC, Greenberg SD. Biopsy and autopsy evaluation of acute rejection versus infection in transplanted lungs. *Lab Invest* 58:14A, 1988.

6. Cagle PT, Truong LD, Weilbaecher DG, Kirkpatrick JB. Thioflavin S versus conventional methods in the detection of amyloid by light microscopy. *Lab Invest* 58:15A, 1988.

7. Cagle PT, Truong LD, Roggli VL, Greenberg SD. Immunohistochemical differentiation between sarcomatous mesotheliomas and other spindle–cell neoplasms. *Am Rev Res Dis* 137:113, 1988.

8. Cagle PT, Thurlbeck WM. Autoradiographic assessment of the sequence of cellular proliferation in post–pneumonectomy lung growth. *Am Rev Res Dis* 137:122, 1988.

9. Cagle PT, Truong LD, Holland VA, Lawrence EC, Greenberg SD. Clinical utility of lung biopsy in the management of lung transplant patients. *Am Rev Res Dis* 137:214, 1988.

10. Cagle PT, Truong LD, Holland VA, Lawrence EC, Rogers BB, Schwartz MR, Kolda T, Buffone GJ, Greenberg SD. Factors contributing to mortality in lung transplant recipients: An autopsy study. *Lab Invest* 60:14A, 1989.

11. Truong L, Mody D, Cagle P, Schwartz M, Wheeler T. Thymic carcinoma: A study of 13 cases. *Lab Invest* 60:98A, 1989.

12. Truong L, Mawad J, Cagle P, Mattioli C. Post–embedding immunoelectron microscopy (IEM) on archival tissue: A study of lupus nephritis and Fanconi's syndrome. *Lab Invest* 60:98A, 1989.

13. Cagle PT, Taylor LD, Schwartz MR, Ramzy I, Elder F. Cytogenetic abnormalities common to adenocarcinoma metastatic to the pleura. *FASEB J* 3:A638, 1989.

14. Cagle PT, Truong LD, Holland VA, Lawrence EC, Greenberg SD. Histopathologic evaluation of pulmonary infection in lung transplant patients. *Chest* 95:180S, 1989.

15. Cagle PT, Holland VA, Samo TC, Buffone GJ, Noon GP, Lawrence EC. Early detection of cytomegalovirus pulmonary infection in a heart–lung transplant patient by polymerase chain reaction amplification. *Lab Invest* 62:14A, 1990.

16. Cagle PT, Langston C, Weilbaecher D, Frost AE, Keller CA, Bayardo RJ. Bronchial neuroendocrine cells in primary pulmonary hypertension. *Chest* 102:94S, 1992.

17. Bailey ME, Cagle PT, Fraire AE, Greenberg SD, Barnard J. Pulmonary histopathology in cocaine abusers. *Chest* 102:139S, 1992.

18. Keller CA, Frost AE, Cagle PT, Young J, Lawrence C, Noon G. Diagnosis and incidence of bronchiolitis obliterans following single, double and heart–lung transplantation. *Chest* 102:74S, 1992.

19. Cagle PT, Brown RW, Lebovitz RM. p53 expression differentiates reactive hyperplasias from malignancy in pleural biopsies. *Mod Pathol* 6:129A, 1993.

20. Cagle PT, Brown RW, Frost A, Kellar C, Yousem SA. Diagnosis of chronic lung transplant rejection by transbronchial biopsy. *Mod Pathol* 6:129A, 1993.

21. Brown RW, Fraire AE, Roggli V, Cagle PT. Assessment of proliferative fraction by PCNA in stage I non–small cell lung cancer. *Mod Pathol* 6:129A, 1993.

22. Frost AE, Keller CA, Noon GP, Short HD, Cagle PT and the Multi–Organ Transplant Group. Outcome of the native lung following single lung transplant. *Am Rev Respir Dis* 147:A599, 1993.

23. Frost AE, Keller CA, Hernandez MM, Noon GP, Short HD, Cagle PT and the Multi–Organ Transplant Group. Recurrence of the original disease following single lung transplantation. *Am Rev Respir Dis* 147:A605, 1993.

24. Subramanian D, Albrecht S, Gonzalez JM, Cagle PT. Primary pulmonary lymphoma: Diagnosis by immunoglobulin gene rearrangement study using a novel polymerase chain reaction technique. *Am Rev Respir Dis* 147:A82, 1993.

25. Younes M, Lebovitz R, Bommer K, Cagle PT, Morton D, Laucirica R. p53 accumulation in non–malignant breast lesions. *Proceedings of the American Association for Cancer Research* 34:195, 1993.

26. Calamari S, Brown RW, Cagle PT. p53 Immunostaining in the differentiation of inflammatory pseudotumor of the lung from sarcoma. *Mod Pathol* 7:149A, 1994.

27. Ostrowski ML, Brown RW, Lebovitz RM, **Cagle PT.** p53 Expression in bronchial biopsies exhibiting squamous metaplastic, atypical and dysplastic features with clinical follow–up. *Mod Pathol* 7:153A, 1994.

28. Bailey ME, Brown RW, Mody DR, **Cagle PT,** Ramzy I. Ber EP4 differentiates adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions: A comparison with CEA, B72.3 and Leu M–1. *Am J Clin Pathol* 101:387, 1994.

29. Frost AE, Brown RW, Pantoja J, **Cagle PT:** Correlation of HLA–Dr monoclonal antibody staining of lung biopsies and diagnosis post lung transplantation. *Chest* 106:112S, 1994.

30. **Cagle PT,** Buffone GJ, Holland VA, Samo TC, Demmler, GJ, Noon GP and Lawrence EC. Semiquantitative measurement of cytomegalovirus DNA in lung and heart–lung transplant patients by *in vitro* DNA amplification. *International Monitor in Respiratory Medicine* (in press).

31. **Cagle PT,** Langston C, Fraire AE, Roggli VL and Greenberg SD. Absence of correlation between nuclear morphometry and survival in Stage I non–small cell lung cancers. *Oncology Digest* (in press).

32. Ledet S, Hoefler G, Conway J, Winter E, Hudnall D, Woeckel W, **Cagle PT,** Popper HH. Detection of Epstein–Barr virus in inflammatory pseudotumor of the lung by polymerase chain reaction and in–situ hybridization. *Mod Pathol* 8:149A, 1995.

33. Conway EJ, Hudnall D, Lazarides A, Bahler A, Fraire AE, **Cagle PT.** In–situ hybridization for EBER–1 RNA in 130 primary neoplasms of the lung and pleura: Absence of evidence for an etiologic role for Epstein–Barr virus. *Mod Pathol* 8:147A, 1995.

34. **Cagle PT,** Fraire AE, Greenberg SD, Rajagopalan S. K–*ras* codon 12 mutations in the pathogenesis of adenocarcinomas associated with atypical epithelium of interstitial pulmonary fibrosis. *Mod Pathol* 8:146A, 1995.

35. Pacinda SJ, Langston C, Gondo MM, Brown RW, Franklin R, Carmona PA, **Cagle PT.** p53 and MDM2 immunostaining in pulmonary blastomas. *Mod Pathol* 8:151A, 1995.

36. **Cagle PT,** Fraire AE, Greenberg SD, Cox A, Brown RW. Potential utility of p53 in differentiation of adenocarcinomas from reactive epithelial atypias of the lung. *Mod Pathol* 8:146A, 1995.

37. Ostrowski ML, Brown RW, Lebovitz RM, Cox A, **Cagle PT.** p53 expression in 410 endobronchial biopsies: Correlation of preinvasive lesions with clinical follow–up. *Mod Pathol* 8:151A, 1995.

38. Mullick SS, Ramzy I, Brown RW, Smith D, Gondo MM, Green LK, **Cagle PT.** Immunoreactive localization of the p53 product in pleural effusions: Practical use in distinguishing benign from malignant cells. *Mod Pathol* 8:42A, 1995.

39. Xu HJ, **Cagle PT**, Hu SX, Li J, Benedict WF. Altered retinoblastoma (RB) and p53 protein status as a synergistic prognostic factor in non-small cell lung carcinoma. *Proceedings of the American Association for Cancer Research* 36:246, 1995.

40. Campagna LB, Dunn JK, **Cagle PT**, Brown RW. Immunohistochemical identification of tumor markers in adenocarcinoma: A diagnostic adjunct in the determination of primary site. *Am Jrnl Clin Pathol* 103:500-501, 1995.

41. Bommer B, Rajagopalan S, Greenberg, SD, **Cagle PT**. K-*ras* 12 mutations in pulmonary mucinous cystic tumor and bronchiolo-alveolar carcinoma: A possible pathogenetic relationship. *FASEB* 9(3):A132, 1995.

42. Anton R, Brown RW, Younes M, Gondo M, Stephenson M, **Cagle PT**. Absence of prognostic significance of *bcl*-2 immunopositivity in non-small cell lung cancer: Analysis of 427 cases. *Mod Pathol* 9:153A, 1996.

43. **Cagle PT**, Frost AE, Stephenson M, Gondo M, Truong LD. Tenascin expression in constrictive bronchiolitis of chronic lung transplant rejection versus bronchiolitis obliterans-organizing pneumonia. *Mod Pathol* 9:154A, 1996.

44. Fraire AE, Klemen H, Mikesell S, Popper HH, **Cagle PT**. Platelet derived growth factor in bronchiolitis obliterans organizing pneumonia. *Mod Pathol* 9:155A, 1996.

45. Khoor A, Whittsett JA, Stephenson M, **Cagle PT**. Correlation between immunoreactivity for surfactant protein B precursor and better prognosis in early stage adenocarcinoma of lung. *Mod Pathol* 9:158A, 1996.

46. Khoor A, Whittsett JA, Stephenson M, **Cagle PT**. Utility of surfactant protein B precursor in differentiating adenocarcinoma of lung and malignant mesothelioma. *Mod Pathol* 9:158A, 1996.

47. Maisch SA, Brown RW, Gondo M, Stephenson M, **Cagle PT**. Rb expression in preinvasive and invasive squamous lesions of the bronchus: Immunohistochemical evaluation of 312 endobronchial biopsies. *Mod Pathol* 9:160A, 1996.

48. Mangano WE, Roggli VL, **Cagle PT**, Churg A. The distinction between desmoplastic mesothelioma and fibrous pleurisy: Histologic criteria and p53 immunostaining. *Mod Pathol* 9:160A, 1996.

49. Wilcox GE, Hudnall D, Gondo M, Stephenson M, Spjut HJ, **Cagle PT**. p53 expression in papillary adenocarcinomas of the lung. *Mod Pathol* 9:164A, 1996.

50. Yi ES, Colby TV, **Cagle PT**, Gondo M, Stephenson M, Harclerode D. Alveolar macrophages express intercellular adhesion molecule-1 (ICAM-1) in hypersensitivity pneumonitis. *Mod Pathol* 9:164A, 1996.

51. Yi ES, Harclerode D, Brown RW, Younes M, Gondo M, Stephenson M, Cagle PT. High c-*erb*B-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. *Mod Pathol* 9:164A, 1996.

52. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Glut1 and Glut3 are significant prognostic indicators in stage I non-small cell lung carcinoma. *Mod Pathol* 9:156A, 1996.

53. Coffey DM, Castro CY, Gondo MM, Stephenson MA, Brown RW, Lebovitz RM, Cagle PT. p16 expression and survival in non-small cell lung cancer: Analysis of 414 cases. *Mod Pathol* 10:162A , 1997.

54. Khoor A, Whitsett JA, Stahlman MT, Stephenson M, Cagle PT. Thyroid transcription factor-1 (TTF-1) differentiates adenocarcinoma of the lung from malignant mesothelioma. *Mod Pathol* 10:166A, 1997.

55. Castro CY, Coffey DM, Stephenson M, Brown RW, Cagle PT. Histopathologic features of mixed pattern adenocarcinomas with bronchioloalveolar component: Clinical significance in 115 tumors. *Mod Pathol* 10:162A , 1997.

56. Coffey DM, Anton RC, Stephenson MA, Cagle PT. Frequency and origin of nonpulmonary metastases to the lungs in a consecutive series of 844 resections for pulmonary malignancy. *Mod Pathol* 10:162A, 1997.

57. Brown RW, Gondo M, Stephenson M, Cagle PT. Prognostic significance of MIB-1 (KI-67) proliferative index in non-small cell lung cancer. *Mod Pathol* 10:161A, 1997.

58. Brown RW, Gondo M, Stephenson M, Cagle PT. Patterns of HBME-1 immunoreactivity differentiate epithelial mesothelioma from adenocarcinoma of the lung. *Mod Pathol* 10:161A, 1997.

59. Marchevsky AM, Patel S, Stephenson MA, Gondo M, Brown RW, Younes M, Yi ES, Benedict WP, Anton RC, Cagle PT. Probabilistic neural networks predict survival in stage I and II non-small cell lung cancer. *Mod Pathol* 10:167A, 1997.

60. Euscher ED, Anton RC, Coffey DM, Stephenson MA, Gondo MM, Genty CE, Truong LD, Cagle PT. Connective tissue remodeling in emphysema: Platelet derived growth factor and tenascin in 123 bullectomy specimens. *Mod Pathol* 10:163A, 1997.

61. Anton RC, Coffey DM, Gondo M, Stephenson MA, Brown RW, Lebovitz RM, Cagle PT. Expression of cyclins D1 and E independently predict prognosis in squamous cell carcinoma of the lung. *Mod Pathol* 10:159A, 1997.

62. Finch CJ, Coffey DM, Stephenson MA, Gondo MM, Genty CE, Myers JL, Cagle PT. Platelet derived growth factor isoforms in the pathogenesis of pulmonary hamartomas. *Mod Pathol* 10:163A, 1997.

63. Finch CJ, Cagle PT, Rajagopalan S, Stephenson MA, Genty CE, Shahab I. Low-grade non-Hodgkin's lymphoma of the lung and interstitial pneumonia. A comparative histologic, immunologic and molecular analysis. *Mod Pathol* 10:163A, 1997.

64. Anton RC, Brown RW, Gondo MM, Stephenson MA, Cagle PT. Correlation of alpha-feto-protein receptor expression to advancing stage and grade of non-small cell lung cancer. *The FASEB Jrnl* 11: A101, 1997.

65. Khoor A, Whitsett JA, Stahlman MT, Stephenson M, Cagle PT. Immunoreactivity for thyroid transcription factor-1 (TTF-1) correlates with better prognosis in early stage adenocarcinoma of the lung. *Amer Jrnl Resp & Crit Care* 155(4):A36, 1997.

66. Zemrus TL, Anton RC, Barrios R, Habib G, Seaver SJ, Wiley KJ, Gondo MM, Carlson NR, King MS, Cagle PT. Expression of SV40 large T antigen (Tag) in 141 human malignant mesotheliomas (MM): A possible etiologic role? *FASEB Jrnl* 12(4):A163, 1998.

67. Zemrus TL, Wiley KJ, Gondo MM, Khan S, Carlson NR, Cagle PT. Simian virus 40 (SV40) and p53 detection by Immunostaining and PCR in human bronchioloalveolar (BACA) carcinomas. *FASEB Jrnl* 12(4):A197, 1998.

68. Seaver SJ, Wiley KJ, Cagle PT. Vitamin D receptor in early stage lung cancer: Potential basis for prevention and therapy. *FASEB Jrnl* 12(4):A197, 1998.

69. Cohen LF, Seaver SJ, Wiley KJ, Gondo MM, Carlson NR, King MS, Cagle PT. Vitamin D receptors in mesotheliomas: Potential basis for hormonal therapy. *FASEB Jrnl* 12(4):A197, 1998.

70. Gondo MM, Cagle PT, Fraire AE, Popper HH. Influence of TFG-B, PDGF-AA and PDGF-AB on tenascin expression in fibroblasts (FB) cultured from human lungs. *Mod Pathol* 11(1):174A, 1998.

71. Amrikachi M, Stephenson MA, Gondo MM, Truong LD, Cagle PT. Bcl-2 and Bax expression in emphysema: Potential role in pathogenesis. *Mod Pathol* 11(1):170A, 1998.

72. Zemrus TL, Gondo MM, Wiley KJ, Cagle PT. Immunodetection of Simian Virus (SV40) in human pulmonary adenocarcinoma. *Mod Pathol* 11(1):182A, 1998.

73. Stephenson MA, Castro CY, Gondo MM, Carlson NR, Cagle PT. NM23.H1/Nucleoside diphosphate kinase an expression in 412 lung carcinomas: Lack of correlation with tumor progression, metastasis, or prognosis. *Mod Pathol* 11(1):180A, 1998.

74. Wang S, Cagle PT, Rooney L, Stephenson MA, Seaver SJ, Fraire AE. Zonal distribution of mast cells in bronchiolitis obliterans organizing pneumonia and interstitial pulmonary fibrosis. *Mod Pathol* 11(1):181A, 1998.

Anton RC, Fraire AE, Bailey ME, Gondo MM, Genty CE, Stephenson MA, **Cagle PT.** Platelet derived growth factor and receptor expression in pulmonary interstitial fibrosis secondary to cocaine abuse. *Mod Pathol* 11(1):4A, 1998.

76. Popper HH, Klemen H, Garrity ER, **Cagle PT,** Husain AN. Recurrent sarcoidosis in transplanted lung – does it exist? A PCR study for myocbacterial DNA in four cases. *Mod Pathol* 11(1):178A, 1998.

77. Montes M, Gondo MM, Wiley KJ, Krishnan B, Brown R, **Cagle PT,** Lechago J, Truong L. The diagnostic and histogenetic significance of the monoclonal antibody "renal cell carcinoma marker". *Mod Pathol* 11(1):89A, 1998.

78. Younes M, Jabara G, **Cagle PT.** Overexpression of the neutral amino acids/glutamine transporter ASCT1 in non-small cell lung carcinomas (NSCLCA) is associated with the better patient survival. *Mod Pathol* 11(1):182A, 1998.

79. Castro CY, Stephenson MA, Gondo MM, **Cagle PT.** Prognostic implications of calbindin-D28k in lung cancer: Analysis of 452 cases. *Mod Pathol* 11(1):172A, 1998

80. Castro CY, Wiley KJ, Carlson NR, Gondo MM, **Cagle PT.** Comparison of demographics and cell cycle regulators in bronchioloalveolar carcinomas (BACA) and solid/acinar adenocarcinomas (SA) versus mixed pattern adenocarcinomas (MPA). *Mod Pathol* 11(1), 172A, 1998.

81. Marchevsky, AM, Wiley KJ, Stephenson MA, **Cagle PT.** Reasoning with uncertainty in pathology: Neural networks may predict survival in stage I and II non-small cell carcinoma of the lung patients. *Mod Pathol* 11:178A, 1998.

82. Byrd-Gloster AL, **Cagle PT,** Glass LF, Messina JL, Whitsett JA, Khoor A. Thyroid transciption factor 1 differentiates between small cell carcinoma of the lung and merkel cell tumor. *Mod Pathol* 12(1):182A, 1999.

83. Cai YC, Roggli VL, Mark E, Xu X, **Cagle PT,** Seaver S, Savas L, Fraire AE. Epidermal growth factor receptor in reactive mesothelial proliferations, epithelial malignant mesothelioma and carcinoma of lung: A study of 114 cases. *Mod Pathol* 12(1):182A, 1999.

84. Sharma A, Seaver SJ, Rodriguez M, **Cagle PT.** JC virus as a possible etiological agent in non-small cell lung carcinomas: A review of 135 cases. *Mod Pathol* 12(1):186A, 1999.

85. Sharma A, Rodriguez M, Truong LT, **Cagle PT.** Utility of calretinin and HBME-1 Immunostaining in differentiating metastatic renal cell carcinoma from malignant mesotheliomas: An immunohistochemical study. *FASEB* 13(4):A363, 1999.

POSTER SESSIONS:

1. **Cagle PT**, Mattioli CA, Gresik MV, Greenberg SD. Immunohistochemical Diagnosis of Pulmonary Eosinophilic Granuloma. American Society of Clinical Pathologists Fall Meeting, Las Vegas, Nevada, November, 1985.

2. **Cagle PT**, McFadden D, McGee F, Truong, L, Dudley A, Thurlbeck WM. An Immuno–histochemical Study of the Histogenesis of Pulmonary Blastoma. International Academy of Pathology, U.S.–Canadian Division Annual Meeting, Chicago, Illinois, March, 1987.

3. **Cagle PT**, Thurlbeck WM. The Effect of Age on the Post–pneumonectomy Adaptive Response in Rabbits. American Thoracic Society Annual Meeting, New Orleans, Louisiana, May, 1987.

4. **Cagle PT**, Truong LD, Weilbaecher DG, Kirkpatrick JB. Thioflavin S versus conventional methods in the detection of amyloid by light microscopy. U.S.–Canadian Academy of Pathology Annual Meeting, Washington, D.C., March, 1988.

5. **Cagle PT**, Truong LD, Holland VA, Lawrence EC, Rogers BB, Schwartz MR, Kolda T, Buffone GJ, Greenberg SD. Factors contributing to mortality in lung transplant recipients: An autopsy study. U.S.–Canadian Academy of Pathology Annual Meeting, San Francisco, California, March, 1989.

6. Truong LD, Mawad J, **Cagle PT**, Mattioli CA. Post–embedding immunoelectron microscopy (IEM) on archival tissue: A study of lupus nephritis and Fanconi's syndrome. U.S.–Canadian Academy of Pathology Annual Meeting, San Francisco, California, March, 1989.

7. Truong L, Mody D, **Cagle PT**, Schwartz M, Wheeler T. Thymic carcinoma: A study of 13 cases. U.S.–Canadian Academy of Pathology Annual Meeting, San Francisco, California, March, 1989.

8. **Cagle PT**, Taylor LD, Schwartz MR, Ramzy I, Elder F. Cytogenetic abnormalities common to adenocarcinoma metastatic to the pleura. Federation of American Societies of Experimental Biology Annual Meeting, New Orleans, Louisiana, March, 1989.

9. **Cagle PT**. The molecular biology of carcinoma of the lung. The Pathology of Occupational Lung Disease: An Update (national meeting), Houston, Texas, May, 1989.

10. **Cagle PT**, Kovach M and Ramzy I. Causes of false results in transthoracic fine needle lung aspirates. American Society of Cytology Annual Meeting, Los Angeles, California, November, 1991.

11. Abu–Farsakh H, Willis SL, Wheeler TM, **Cagle PT**. Histogenesis of giant cell component in carcinoma of the lung. Texas Society of Pathology Annual Meeting, Fort Worth, Texas, January, 1992.

2. Hicks J, Flaitz C, Wong M, McDaniel K, **Cagle PT**. Calcifying epithelial odontogenic tumor of the mandible: A case report. Texas Society of Pathology Annual Meeting, Fort Worth, Texas, January, 1992.

13. Subramanian D, Gonzalez JM, Albrecht S, **Cagle PT**. Pulmonary infiltrates and macroglobulinemia. Department of Medicine Research Poster Symposium, Houston, Texas, April, 1992.

14. Bailey ME, **Cagle PT**, Fraire AE, Greenberg SD, Barnard J. Pulmonary histopathology in cocaine abusers. American College of Chest Physicians 58th Annual Scientific Assembly, Chicago, Illinois, October, 1992.

15. Subramanian D, Gonzalez JM, Albrecht S, **Cagle PT**. Pulmonary infiltrates and macroglobulinemia. American College of Chest Physicians 58th Annual Scientific Assembly, Chicago, Illinois, October, 1992.

16. **Cagle PT**, Brown RW, Lebovitz RM. p53 expression differentiates reactive hyperplasias from malignancy in pleural biopsies. United States and Canadian Academy of Pathology 82nd Annual Meeting, New Orleans, Louisiana, March, 1993.

17. **Cagle PT**, Brown RW, Yousem SA. Diagnosis of chronic lung transplant rejection by transbronchial biopsy. United States and Canadian Academy of Pathology 82nd Annual Meeting, New Orleans, Louisiana, March, 1993.

18. Hazbun M, Alvarez J, **Cagle PT**, Eschenbacher WL. Ozone exposure does not result in increased inflammatory infiltrate in bronchial biopsies in human subjects. American Thoracic Society International Conference. San Francisco, California, May 17, 1993.

19. Frost AE, Keller CA, Noon GP, Short HD, **Cagle PT** and the Multi–Organ Transplant Group. Outcome of the native lung following single lung transplant. American Thoracic Society International Conference, San Francisco, California, May 17, 1993.

20. Frost AE, Keller CA, Hernandez MM, Noon GP, Short HD, **Cagle PT** and the Multi–Organ Transplant Group. Recurrence of the original disease following single lung transplantation. American Thoracic Society International Conference, San Francisco, California, May 17, 1993.

21. Younes M, Lebovitz R, Bommer K, **Cagle PT**, Morton D, Laucirica R. p53 accumulation in non–malignant breast lesions. Proceedings of the American Association for Cancer Research, Orlando, Florida, May, 1993.

22. **Cagle PT**, Cooley LD, Wilson D, Morton D, Cartwright J, Mawad J, Darlington G. Expression of c–*myc* in non–small cell lung cancer cell lines. International Academy of Chest Physicians and Surgeons, XVII World Congress on Diseases of the Chest, Amsterdam, The Netherlands, June 15, 1993.

23. Cagle PT, Mody DR, Brown RW, Schwartz MR. Glucocorticoid receptors in non–small cell carcinoma of the lung. International Academy of Chest Physicians and Surgeons, XVII World Congress on Diseases of the Chest, Amsterdam, The Netherlands, June 15, 1993.

24. Calamari S, Brown RW, Cagle PT. p53 immunostaining in the differentiation of inflammatory pseudotumor of the lung from sarcoma. Texas Society of Pathology Annual Meeting, Austin, Texas, January, 1994.

25. Calamari S, Brown RW, Cagle PT. p53 Immunostaining in the differentiation of inflammatory pseudotumor of the lung from sarcoma. United States and Canadian Academy of Pathology 83rd Annual Meeting, San Francisco, California, March 15, 1994.

26. Ostrowski ML, Brown RW, Lebovitz RM, Cagle PT. p53 Expression in bronchial biopsies exhibiting squamous metaplastic, atypical and dysplastic features with clinical follow–up. United States and Canadian Academy of Pathology 83rd Annual Meeting, San Francisco, California, March 15, 1994.

27. Bailey ME, Brown RW, Mody DR, Cagle PT, Ramzy I. Ber EP4 differentiates adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions: A comparison with CEA, B72.3 and Leu M–1. American Society of Clinical Pathologists/ College of American Pathologists Spring National Meeting Scientific Sessions, Seattle, Washington, April, 1994.

28. Frost AE, Brown RW, Pantoja J, Cagle PT: Correlation of HLA–Dr Monoclonal Antibody Staining of Lung Biopsies and Diagnosis Post Lung Transplantation. American College of Chest Physicians 60th Annual International Scientific Assembly, New Orleans, Louisiana, November 1, 1994.

29. Ledet S, Hoefler G, Conway J, Winter E, Hudnall D, Woeckel W, Cagle PT, Popper HH. Detection of Epstein–Barr virus in inflammatory pseudotumor of the lung by polymerase chain reaction and in–situ hybridization. United States and Canadian Academy of Pathology 84th Annual Meeting, Toronto, Ontario, March 13, 1995.

30. Conway EJ, Hudnall D, Lazarides A, Bahler A, Fraire AE, Cagle PT. In–situ hybridization for EBER–1 RNA in 130 primary neoplasms of the lung and pleura: Absence of evidence for an etiologic role for Epstein–Barr virus. United States and Canadian Academy of Pathology 84th Annual Meeting, Toronto, Ontario, March 13, 1995.

31. Pacinda SJ, Langston C, Gondo MM, Brown RW, Franklin R, Carmona PA, Cagle PT. p53 and MDM2 immunostaining in pulmonary blastomas. United States and Canadian Academy of Pathology 84th Annual Meeting, Toronto, Ontario, March 13, 1995.

32. Cagle PT, Fraire AE, Greenberg SD, Cox A, Brown RW. Potential utility of p53 in differentiation of adenocarcinomas from reactive epithelial atypias of the lung. United States and Canadian Academy of Pathology 84th Annual Meeting, Toronto, Ontario, March 15, 1995.

33. Ostrowski ML, Brown RW, Lebovitz RM, Cox A, **Cagle PT.** p53 expression in 410 endobronchial biopsies: Correlation of preinvasive lesions with clinical follow–up. United States and Canadian Academy of Pathology 84th Annual Meeting, Toronto, Ontario, March 14, 1995.

34. Mullick SS, Ramzy I, Brown RW, Smith D, Gondo MM, Green LK, **Cagle PT.** Immunoreactive localization of the p[53 product in pleural effusions: Practical use in distinguishing benign from malignant cells. United States and Canadian Academy of Pathology 84th Annual Meeting, Toronto, Ontario, March 13, 1995.

35. Xu HJ, **Cagle PT,** Hu SX, Li J, Benedict WF. Altered retinoblastoma (RB) and p53 protein status as a synergistic prognostic factor in non-small cell lung carcinoma. American Association for Cancer Research 86th Annual Meeting, Toronto, Ontario, March 14, 1995.

36. Bommer B, Rajagopalan S, Greenberg SD, Fraire AE, **Cagle PT.** K-*ras* codon 12 mutations in pulmonary mucinous cystic tumor and bronchioloalveolar carcinoma: a possible pathogenetic relationship. Federation of American Societies of Experimental Biology Annual Meeting, Atlanta, Georgia, April 10, 1995.

37. Hite W, Masciangelo T, Martin AA, **Cagle PT.** Anterior mediastinal mass presenting as a chronic cough with normal chest reontgenogram. Southern Medical Association Annual Meeting, Kansas City, MO, November, 1995.

38. Wilcox GE, Hudnall D, Gondo M, Stephenson M, Spjut H, **Cagle PT.** p53 expression in papillary adenocarcinomas of the lung. United States and Canadian Academy of Pathology 85th Annual Meeting, Washington, D.C., March 25, 1996.

39. Anton R, Brown RW, Younes M, Gondo M, Stephenson M, **Cagle PT.** Absence of prognostic significance of bcl-2 immunopositivity in non-small cell lung cancer: Analysis of 427 cases. United States and Canadian Academy of Pathology 85th Annual Meeting, Washington, D.C., March 25, 1996.

40. Mangano WE, Roggli VL, **Cagle PT,** Churg A. The distinction between desmoplastic mesothelioma and fibrous pleurisy: Histologic criteria and p53 immunostaining. United States and Canadian Academy of Pathology 85th Annual Meeting, Washington, D.C., March 26, 1996.

41. Khoor A, Whittsett JA, Stephenson M, **Cagle PT.** Utility of surfactant protein B precursor in differentiating adenocarcinoma of lung and malignant mesothelioma. United States and Canadian Academy of Pathology 85th Annual Meeting, Washington, D.C., March 26, 1996.

42. Khoor A, Whittsett JA, Stephenson M, **Cagle PT.** Correlation between immunoreactivity for surfactant protein B precursor and better prognosis in early stage adenocarcinoma of lung. United States and Canadian Academy of Pathology 85th Annual Meeting, Washington, D.C., March 26, 1996.

Younes M, Brown RW, Stephenson M, Gondo M, **Cagle PT.** Glut1 and Glut3 are significant prognostic indicators in stage I non-small cell lung carcinoma. United States and Canadian Academy of Pathology 85th Annual Meeting, Washington, D.C., March 27, 1996.

44. Finch CJ, Coffey DM, Stephenson MA, Gondo MM, Genty CE, Myers JL, **Cagle PT.** Platelet derived growth factor isoforms in the pathogenesis of pulmonary hamartomas. Texas Society of Pathologists Annual Meeting, Corpus Christi, Texas, January 31, 1997.

45. Finch CJ, **Cagle PT,** Rajagopalan S, Stephenson MA, Genty CE, Shahab I. Low grade non-Hodgkin's lymphoma of the lung and interstitial pneumonia. A comparative histologic, immunologic and molecular analysis. Texas Society of Pathologists annual Meeting, Corpus Christi , Texas, January 31, 1997.

46. Khoor A, Whitsett JA, Stahlman MT, Stephenson M, **Cagle PT.** Thyroid transcription factor-1 (TTF-1) differentiates adenocarcinoma of the lung from malignant mesothelioma. United States-Canadian Academy of Pathology, 86th Annual Meeting, Orlando, Florida, March 4, 1997.

47. Castro CY, Coffey DM, Wiley KJ, Stephenson MA, Brown RW, **Cagle PT.** Histopathologic features of mixed pattern adenocarcinomas with bronchioloalveolar component: Clinical significance in 115 tumors. United States-Canadian Academy of Pathology, 86th Annual Meeting, Orlando, Florida, March 3, 1997.

48. Coffey DM, Anton RC, Stephenson MA, **Cagle PT.** Frequency and origin of nonpulmonary metastases to the lungs in a consecutive series of 844 resections for pulmonary malignancy. United States-Canadian Academy of Pathology, 86th Annual Meeting, Orlando, Florida, March 5, 1997.

49. Brown RW, Gondo M, Stephenson M, **Cagle PT.** Prognostic significance of MIB-1 (KI-67) proliferative index in non-small cell lung cancer. United States-Canadian Academy of Pathology, 86th Annual Meeting, Orlando, Florida, March 5, 1997.

50. Brown RW, Gondo M, Stephenson M, **Cagle PT.** Patterns of HBME-1 immunoreactivity differentiate epithelial mesothelioma from adenocarcinoma of the lung. United States-Canadian Academy of Pathology, 86th Annual Meeting, Orlando, Florida, March 4, 1997.

51. Marchevsky AM, Patel S, Stephenson MA, Gondo M, Brown RW, Younes M, Yi ES, Benedict WP, Anton RC, **Cagle PT.** Probabilistic neural networks predict survival in stage I and II non-small cell lung cancer. United States-Canadian Academy of Pathology, 86th Annual Meeting, Orlando, Florida, March 4, 1997.

52. Euscher ED, Anton RC, Coffey DM, Wiley KJ, Stephenson MA, Gondo MM, Genty CE, Truong LD, **Cagle PT.** Connective tissue remodeling in emphysema: platelet derived growth factor and tenascin in 123 bullectomy specimens. United States-Canadian Academy of Pathology, 86th Annual Meeting, Orlando, Florida, March 5, 1997.

53. Anton RC, Coffey DM, Gondo MM, Stephenson MA, Brown RW, Lebovitz RM, **Cagle PT.** Expression of cyclins D1 and E independently predict prognosis in squamous cell carcinoma of the lung. United States-Canadian Academy of Pathology, 86th Annual Meeting, Orlando, Florida, March 3, 1997.

54. Finch CJ, Coffey DM, Stephenson MA, Gondo MM, Genty CE, Myers JL, **Cagle PT.** Platelet derived growth factor isoforms in the pathogenesis of pulmonary hamartomas. United States-Canadian Academy of Pathology, 86th Annual Meeting, Orlando, Florida, March 4, 1997.

55. Finch CJ, **Cagle PT,** Rajagopalan S, Stephenson MA, Genty CE, Shahab I. Low grade non-Hodgkin's lymphoma of the lung and interstitial pneumonia. A comparative histologic, immunologic and molecular analysis. United States-Canadian Academy of Pathology, 86th Annual Meeting, Orlando, Florida, March 4, 1997.

56. Khoor A, Whitsett JA, Stahlman MT, Stephenson M, **Cagle PT.** Immunoreactivity for throid transcription factor-1 (TTF1) correlates with better prognosis in early stage adenocarcinoma of the lung. American Thoracic International Conference, San Francisco, CA, May 1997.

57. Zemrus TL, Gondo MM, Wiley KJ, **Cagle PT.** Immunodetection of simian virus 40 (SV40) virus in human pulmonary adenocarcinoma. Texas Society of Pathologists 77th Annual Meeting, Houston, TX, February 5-8, 1998.

58. Amrikachi M, Stephenson MA, Gondo MM, Truong LD, **Cagle PT.** Bcl-2 and Bax expression in emphysema: Potential role in pathogenesis. Texas Society of Pathologists 77th Annual Meeting, Houston, TX, February 5-8, 1998.

59. Castro CY, Stephenson MA, Gondo MM, **Cagle PT.** Prognostic implications of calbindin-D28k in lung cancer: Analysis of 452 cases. Texas Society of Pathologists 77th Annual Meeting, Houston, TX, February 5-8, 1998.

60. Castro CY, Wiley KJ, Carlson NR, Gondo MM, **Cagle PT.** Comparison of demographics and cell cycle regulators in bronchioloalveolar carcinomas (BACA) and solid/acinar adenocarcinomas (SA) versus mixed pattern adenocarcinomas (MPA). Texas Society of Pathologists 77th Annual Meeting, Houston, TX, February 5-8, 1998.

61. Castro CY, Wiley KJ, Seaver SJ, Carlson NR, Gondo MM, King MS, **Cagle PT.** Altered expression of cell cycle regulators in malignant mesotheliomas (MM). Texas Society of Pathologists 77th Annual Meeting, Houston, TX, February 5-8, 1998.

62. Gondo MM, **Cagle PT,** Fraire AE, Popper HH. Influence of TFG-B, PDGF-AA and PDGF-AB on tenascin expression in fibroblasts (FB) cultured from human lungs. United States-Canadian Academy of Pathology, 87th Annual Meeting, Boston, MA, March 2, 1998.

63. Amrikachi M, Stephenson MA, Gondo MM, Truong LD, **Cagle PT.** Bcl-2 and Bax expression in emphysema: Potential role in pathogenesis. United States-Canadian Academy of Pathology, 87th Annual Meeting, Boston, MA, March 2, 1998.

64. Zemrus TL, Gondo MM, Wiley KJ, **Cagle PT.** Immunodetection of Simian Virus (SV40) in human pulmonary adenocarcinoma. United States-Canadian Academy of Pathology, 87th Annual Meeting, Boston, MA, March 2, 1998.

65. Stephenson MA, Castro CY, Gondo MM, Carlson NR, **Cagle PT.** NM23.H1/Nucleoside diphosphate kinase an expression in 412 lung carcinomas: Lack of correlation with tumor progression, metastasis, or prognosis. United States-Canadian Academy of Pathology, 87th Annual Meeting, March 2, 1998.

66. Wang, S, **Cagle PT,** Rooney L, Stephenson MA, Seaver SJ, Fraire AE. Zonal distribution of mast cells in bronchiolitis obliterans organizing pneumonia and interstitial pulmonary fibrosis. United States-Canadian Academy of Pathology, 87th Annual Meeting, March 2, 1998.

67. Liu LW, Krishanan B, Gondo MM, Wiley KJ, **Cagle PT,** Lechago J, Truong L. Expression of BAX protein in renal cell carcinoma (RCC): Correlation with other determinants of tumor cell apoptosis (AP). United States-Canadian Academy of Pathology, 87th Annual Meeting, March 2, 1998.

68. Anton RC, Fraire AE, Bailey ME, Gondo MM, Genty CE, Stephenson MA, **Cagle PT.** Platelet derived growth factor and receptor expression in pulmonary interstitial fibrosis secondary to cocaine abuse. United States-Canadian Academy of Pathology, 87th Annual Meeting, March 2, 1998.

69. Popper HH, Klemen H, Garrity ER, **Cagle PT,** Husain AN. Recurrent sarcoidosis in transplanted lung – does it exist? A PCR study for myocbacterial DNA in four cases. United States-Canadian Academy of Pathology, 87th Annual Meeting, March 2, 1998.

70. Montes M, Gondo MM, Wiley KJ, Krishnan B, Brown R, **Cagle PT,** Lechago J, Truong L. The diagnostic and histogenetic significance of the monoclonal antibody "renal cell carcinoma marker". United States-Canadian Academy of Pathology, 87th Annual Meeting, March 3, 1998.

71. Younes, M, Jabara G., **Cagle PT.** Overexpression of the neutral amino acids/glutamine transporter ASCT1 in non-small cell lung carcinomas (NSCLCA) is associated with the better patient survival. United States-Canadian Academy of Pathology, 87th Annual Meeting, March 4, 1998.

72. Castro CY, Stephenson MA, Gondo MM, **Cagle PT.** Prognostic implications of calbindin-D28k in lung cancer: Analysis of 452 cases. United States-Canadian Academy of Pathology, 87th Annual Meeting, March 4, 1998.

73. Marchevsky AM, Wiley KJ, Stephenson MA, **Cagle PT.** Reasoning with uncertainty in pathology: Neural networks may predict survival in stage I and II non-small cell carcinoma of the lung patients. United States-Canadian Academy of Pathology, 87th Annual Meeting, Boston, MA, March 4, 1998.

74. Seaver SJ, Wiley KJ, **Cagle PT**. Vitamin D receptor in early stage lung cancer: Potential basis for prevention and therapy. Federation for the Advancement of Science and Experimental Biology '98, San Francisco, CA, April 19, 1998.

75. Cohen LF, Seaver SJ, Wiley KJ, Gondo MM, Carlson NR, King MS, **Cagle PT**. Vitamin D receptors in mesotheliomas: Potential basis for hormonal therapy. Federation for the Advancement of Science and Experimental Biology '98, San Francisco, CA, April 19, 1998.

76. Zemrus, TL, Wiley KJ, Gondo MM, Khan S, Carlson NR, **Cagle PT**. Simian Virus (SV40) and p53 detection by immunostaining and PCR in human bronchioloalveolar (BACA) carcinomas. Federation for the Advancement of Science and Experimental Biology '98, San Francisco, CA, April 19, 1998.

77. Byrd-Gloster AL, **Cagle PT**, Glass LF, Messina JL, Whitsett JA, Khoor A. Thyroid transcription factor 1 differentiates between small cell carcinoma of the lung and merkel cell tumor. United States and Canadian Academy of Pathology 88th Annual Meeting, San Francisco, CA, March 22, 1999.

78. Sharma A, Seaver SJ, Rodriguez M, **Cagle PT**. JC virus as a possible etiological agent in non-small cell lung carcinomas: A review of 135 cases. United States and Canadian Academy of Pathology 88th Annual Meeting, San Francisco, CA, March 24, 1999.

INVITED LECTURES/COURSES:

Pulmonary Scar Cancers. **Cagle PT**, Department of Pathology, Washington University School of Medicine, St. Louis, Missouri, September 17, 1984.

Asma y Neumonias Eosinofilicas. **Cagle PT**, Colegio de Médicos, San Jose, Costa Rica, May 22, 1989.

Lavado Broncoalveolar. **Cagle PT**, Hospital Calderón Guardia, San Jose, Costa Rica, May 23, 1989.

Patologia de la Obstrucción Crónica al Flujo Aéreo. **Cagle PT**, Colegio de Médicos, San Jose, Costa Rica, May 23, 1989.

Biologia Molecular del Cancer Pulmonar. **Cagle PT**, Hospital San Juan de Dios, San Jose, Costa Rica, May 24, 1989.

Fibrosis Pulmonar. Patologia y Diagnóstico Diferencial. **Cagle PT**, Colegio de Médicos, San Jose, Costa Rica, May 24, 1989.

Patologia del Transplante Pulmonar. **Cagle PT**, Hospital México, San Jose, Costa Rica, May 26, 1989.

SIDA y el Pulmón Patholgia. **Cagle PT**, Colegio de Médicos, San Jose, Costa Rica, May 26, 1989.

The Pathology of Lung Transplantation. **Cagle PT**, Houston Society of Clinical Pathologists, Houston, Texas, June 23, 1989.

Molecular Biology of Lung Cancer. **Cagle PT**, Second Annual Baylor Pathology Scientific Meeting of Alumni and Friends, Houston, Texas, October 20, 1989.

Molecular Biology of Lung Cancer. **Cagle PT**, Northwestern University School of Medicine, Chicago, Illinois, November 14, 1989.

Application of Molecular Biology to Surgical Pathology of the Lung. **Cagle PT**, Third Annual Baylor Pathology Scientific Meeting of Alumni and Friends, Houston, Texas, October 27, 1990.

Basic Aspects of Oncogenesis. **Cagle, PT**, Postgraduate Course on Lung Cancer, American College of Chest Physicians, Toronto, Ontario, October 1990.

Prevention and Screening of Lung Cancer. **Cagle PT**, Symposium on Cancer Prevention at the Work Site, Texas Occupational Medicine Association, Houston, Texas, October 1990.

Application of Molecular Markers for Biologic Behavior in the Evaluation of Lung Cancer. **Cagle PT**, Fourth Annual Baylor Scientific Meeting of Alumni and Friends, Houston, Texas, October 12, 1991.

Molecular Biology of Lung Cancer. **Cagle PT**, Symposium on New Concepts in Lung Cancer Molecular Biology, American College of Chest Physicians, San Francisco, California, November 5, 1991.

Molecular Pathology of Lung Cancer and Its Clinical Relevance. **Cagle PT**, United States–Canadian Academy of Pathology Long Course 1993 – Current Topics in Pulmonary Pathology, New Orleans, Louisiana, March 17, 1993.

Update in Pulmonary Pathology. **Cagle PT**, Program Director, Houston Society of Clinical Pathologists Scientific Seminar, Houston, Texas, April 24, 1993.

Diagnostic Dilemmas in Pulmonary Neoplasia. **Cagle PT**, Greenberg SD, American Society of Clinical Pathologists Workshop, Chicago, Illinois, March 27, 1993.

Biology of Small Cell Lung Cancer. **Cagle PT**, International Academy of Chest Physicians and Surgeons, XVII World Congress on Diseases of the Chest, Amsterdam, The Netherlands, June 16, 1993.

Molecular Pathology of Lung Cancer. **Cagle PT**, University of California, Davis Medical Center, Sacramento, California, September 27, 1993

Molecular Pathology of Lung Cancer. **Cagle PT**, University of British Columbia, Vancouver, B.C., Canada, September 29, 1993.

Lung Pathology in Lung and Heart–Lung Transplantation. **Cagle PT**, University of British Columbia, Vancouver, B.C., Canada, September 30, 1993.

Molecular Pathology of Lung Cancer. **Cagle PT**, M.D. Anderson Cancer Hospital Oncology Seminar, Houston, Texas, October 13, 1993.

Wegener's Granulomatosis. **Cagle PT**, United States–Canadian Academy of Pathology Pulmonary Pathology Specialty Conference, San Francisco, California, March 17, 1994.

Molecular Pathology of Lung Cancer. **Cagle PT**, American College of Chest Physicians Postgraduate Course in Lung Pathology, Chicago, Illinois, April 7, 1994.

Sarcoid and Necrotizing Sarcoid. **Cagle PT**, American College of Chest Physicians Postgraduate Course in Lung Pathology, Chicago, Illinois, April 9, 1994.

Molecular Pathology in the Diagnosis and Treatment of Lung Cancer. **Cagle PT**, Master Teacher Scientific Session: American College of Chest Physicians 60th Annual International Scientific Assembly, New Orleans, Louisiana, November 3, 1994.

Update on the Pathologic Diagnosis of Pneumoconioses. **Cagle PT**, Armed Forces Institute of Pathology Specialty Course on Pathology of the Respiratory Tract and Mediastinum, San Antonio, Texas, February 18, 1995.

Surgical Pathology of Tumors of the Pleura. **Cagle PT**, Armed Forces Institute of Pathology Specialty Course on Pathology of the Respiratory Tract and Mediastinum, San Antonio, Texas, February 18, 1995.

The Pathology of Lung Transplants and Rejection-Associated Changes. **Cagle PT**, Seminars in Surgical Pathology, University of Massachusetts Medical Center, Worcester, Massachusetts, April 26, 1995.

The Molecular Biology of Lung Cancer. **Cagle PT**, Medical Grand Rounds, University of Massachusetts Medical Center, Worcester, Massachusetts, April 27, 1995.

The Molecular Pathology of Lung Cancer. **Cagle PT**. Pulmonary and Critical Care Medicine Research Conference Series. Baylor College of Medicine, Houston, Texas, May 3, 1995.

The Molecular Pathology of Lung Cancer. **Cagle PT**, Scientific Union of the Evangelismos Hospital, Athens, Greece, June 14, 1995.

Diagnostic Dilemmas in Pulmonary Neoplasia. **Cagle PT**, Director, American Society of Clinical Pathologists Workshop, New Orleans, Louisiana, September 18, 1995.

A Practical Approach to Interstitial Lung Diseases for the Surgical Pathologist. **Cagle PT.** Houston Society of Clinical Pathologists., Houston, Texas, January 24, 1996.

Pulmonary Pathology Section, United States and Canadian Academy of Pathology. **Cagle PT,** Colby T, Moderators; Washington, D.C.; March 1996.

Molecular Pathology of Lung Cancer. **Cagle PT.** American College of Chest Physicians Postgraduate Course in Lung Pathology, Phoenix, Arizona, June, 1996.

Cytology. **Cagle PT.** American College of Chest Physicians Postgraduate Course in Lung Pathology, Phoenix, Arizona, June, 1996.

Diagnostic Dilemmas in Lung Transplant Biopsy, XVIII World Congress on Diseases of the Chest, San Francisco, California, October 29, 1996.

Pulmonary Pathology Society. Roggli V, **Cagle PT,** Moderators, Second Annual Meeting, Orlando, Florida, March 1, 1997.

Pulmonary Pathology Section, United States and Canadian Academy of Pathology. **Cagle PT,** Brambilla E, Moderators. United States-Canadian Academy of Pathology, 87th Annual Meeting, March 3, 1998.

Practical Approach to Interstitial Lung Diseases for the Surgical Pathologist. **Cagle PT.** *Dr. Bobby Miller Memorial Lecture*, University of British Columbia, Department of Pathology, Vancouver, British Columbia, Canada, May 21-22, 1998.

Molecular Pathology of Lung Cancer. **Cagle PT.** Visiting Physician Education Program, Italian Ministry of Health, Baylor College of Medicine, Houston, TX, June 15, 1998.

Molecular Pathology of Lung Cancer. **Cagle PT.** American College of Chest Physicians Postgraduate Course in Lung Pathology, Washington, D.C., September, 1998.

Cytology. **Cagle PT.** American College of Chest Physicians Postgraduate Course in Lung Pathology, Washington, D.C., September 10, 1998.

Molecular Pathology of Lung Cancer. **Cagle PT.** Visiting Physician Education Program, Italian Ministry of Health, Baylor College of Medicine, Houston, TX, October 6, 1998.

Sarcomatoid Mesothelioma and Other Sarcomas. **Cagle PT.** XXII International Congress of the International Academy of Pathology and 13th World Congress of Academic and Environmental Pathology; Nice, France, October 20, 1998.

New Approach to the Pathologic Diagnosis of Interstitial Lung Diseases. **Cagle PT** Institute of Pathology and Laboratory of Environmental & Respiratory Pathology, University of Graz Medical School, Graz, Austria, March 10, 1999.

Pathology of Pulmonary Granulomatoses. **Cagle PT.** Austrian Society of Pathology Annual Meeting, Vienna, Austria, March 13, 1999.

Cagle PT. Session on Pulmonary Neoplasia, Pulmonary Pathology Society Meeting, Asheville, NC, August 25, 1999.

INVITED MEDIA APPEARANCES:

Cagle PT, Television Interview on Molecular Pathology of Lung Cancer, broadcast on *JAMA Medical Rounds* , CNBC network, May 8, 1994.

Cagle PT, Television Interview, broadcast on NBC Nightly News, NBC network, March, 1998.

TELECONFERENCES:

What's New in the Pathology of Lung Cancer . **Cagle PT,** American Society of Clinical Pathologists Spring 1994 Teleconference Series, November 11, 1994.

Immunohistochemical identification of tumor markers in metastatic adenocarcinoma (Where is the primary?). Anton RC, **Cagle PT.** American Society of Clinical Pathologists Spring 1998 Teleconference Series, April 3, 1998.

TEACHING INFORMATION:

Teaching Assistant, General Pathology Course for first year medical students, Baylor College of Medicine, Houston, Texas, 1987–89.

Lectures on Pulmonary Pathology, Basic Science Pathology Course for first year medical students, Baylor College of Medicine, Houston, Texas, 1988, 1992 – present

Lectures on Pulmonary Pathology, Didactic conferences for Pathology residents, Baylor College of Medicine, Houston, Texas, 1988–present.

Lectures on Pulmonary Pathology, Houston Community College Respiratory Therapy RTT 2206, Houston, Texas, 1988–90.

Lectures on Pathology of Occupational Lung Disease, University of Texas School of Public Health, 1992.

Lectures on Pathology of Lung Cancer, Radiation Oncology, Baylor College of Medicine, 1993.

Lectures on Pulmonary Pathology, Basic Science Pathology Course for first year medical students, Texas A&M University, College Station, Texas, 1994–present.

Faculty, The Pathology of Occupational Lung Disease: An Update (national meeting), Houston, Texas, May, 1989.

Faculty, Update in Pulmonary Medicine (regional meeting), Houston, Texas, October 25–26, 1991.

Faculty, American College of Chest Physicians Postgraduate Course in Lung Pathology, Chicago, Illinois, April 6–10, 1994.

Master Teacher, American College of Chest Physicians 60th Annual International Scientific Assembly, New Orleans, October 31–November 3, 1994.

Faculty, XVIII World Congress on Diseases of the Chest, San Francisco, California, October 27-31, 1996.

Faculty, American College of Chest Physicians Postgraduate Course in Lung Pathology, Phoenix, Arizona, June, 1996.

Faculty, American College of Chest Physicians Postgraduate Course in Lung Pathology, Washington, DC, September 1998.

Faculty, XXII International Congress of the International Academy of Pathology and the 13th World Congress of Academic and Environmental Pathology, Nice, France, October 1998.

CONFERENCES:

Director, Monthly Pulmonary Pathology/Radiology Conference, Baylor College of Medicine, Houston, Texas.

Pathology Director, Weekly Chest Conference, The Methodist Hospital, Houston, Texas.

CURRICULUM VITAE

Morton Corn

PERSONAL DATA

Home Address

1714 Eutaw Place
Baltimore, MD 21217
(410) 383-0868

Business Address

The Johns Hopkins University
Department of Environmental Health Sciences
Division of Environmental Health Engineering
615 North Wolfe Street, Room 6010
Baltimore, MD 21205
Phone: (410) 955-3602
Fax: (410) 955-9334

EDUCATION AND TRAINING

Degree	Year	Institution	Field
B.Ch.E.	06/55	The Cooper Union New York, NY	Chemical Engineering
M.S.	06/56	Harvard University Division of Engineering and Applied Physics Cambridge, MA	Industrial Hygiene and Sanitary Engineering
Ph.D.	01/61	Harvard University Division of Engineering and Applied Physics Cambridge, MA	Industrial Hygiene and Sanitary Engineering

Postdoctoral Training

National Science Foundation Postdoctoral Fellow, London School of Hygiene and Tropical Medicine, University of London, Medical Research Council, London, England, 1961-62.

Guggenheim Fellow, London, England, 1972-73.

Board Certification

Board of Certified Safety Professionals, Parkridge, Illinois (Certificate No. 1869).

PROFESSIONAL EXPERIENCE

Professor and Division Director, February 1, 1980 - present, The Johns Hopkins University, School of Hygiene and Public Health, Department of Environmental Health Sciences, Division of Environmental Health Engineering; Director, July 1982 - present, NIOSH Educational Resource Center in Occupational Safety and Health; Director, June 1990 - present, National Institute of Environmental Health Sciences Research Center.

Assistant Secretary of Labor, December 2, 1975 - January 20, 1977, Occupational Safety and Health, United States Department of Labor, Washington, D.C.

Professor, August 1967 - December 1979, University of Pittsburgh, Department of Industrial Environmental Health Sciences (formerly Department of Occupational Health) and Adjunct Professor, Department of Chemical Engineering; Associate Professor, June 1965 - August 1967, University of Pittsburgh, Department of Occupational Health; Associate Professor, September 1965 - July 1966, Department of Public Health Practice; Assistant Professor, September 1962 - September 1965; Department of Public Health Practice; Adjunct Assistant Professor, 1965, Chemical Engineering; Visiting Fellow, 1964-68, Mellon Institute (Industrial Hygiene Foundation).

Research Associate, September 1960 - August 1961, Harvard School of Public Health, School of Engineering and Applied Sciences. Joint appointment in Departments of Industrial Hygiene and Physiology.

USPHS Fellow, September 1958 - August 1960, Harvard School of Public Health, School of Engineering and Applied Sciences.

Project Engineer, July 1956 - August 1958, Robert A. Taft Sanitary Engineering Center, United States Public Health Service, Cincinnati, Ohio. Military service fulfilled while Project Engineer. Presently in USPHS Inactive Reserve. Permanent Grade: Sanitary Engineer Director.

Research Aide, June 1954 - September 1954; United States Atomic Energy Commission, Health and Safety Laboratory, New York, NY.

PROFESSIONAL ACTIVITIES

Societies/Memberships

Delta Omega (Honorary Public Health), 1955-present
Air Pollution Control Association, Member 1957-1994; TR-1 Research Committee, 1966-67; Member, Technical Council, 1973-75; Vice Chairman, Committee on Indoor Air Pollution, 1977

PROFESSIONAL ACTIVITIES

Societies/Memberships (cont'd)

American Industrial Hygiene Association, 1959-
American Chemical Society: Member, Senior Grade, 1959-73; 1992-
Sigma XI: Senior Member, 1960-1989
British Occupational Hygiene Society, 1962-
American Institute of Chemical Engineers: Member, Full Grade, 1963-
American Public Health Association: Fellow, 1964-
American Industrial Hygiene Association, Member, Technical Committee for Air Pollution Evaluation, 1964-67; Member, Technical Committee for Aerosol Technology, 1966-69; Member, Management Committee, 1982-85; Member, Long Range Planning Committee, 1990-
Intersociety Committee for Standardization of Air Sampling Methods, Member, Sulfur Compounds Subcommittee, 1965-68
American Association of University Professors, 1967-91
American Conference of Governmental Industrial Hygienists, 1968-; Vice Chairman Elect, 1982; Vice Chairman, 1983; Chairman, 1984; Awards Committee, 1984-1990
American Association for the Advancement of Science, 1969-75; 1982-84
Society of Occupational and Environmental Health: Founding Member, 1972-86; Councilor, 1973-76; 1981-84; Chairman, NIOSH Criteria Document Review Committee, 1974-75; Chairman, Engineering Committee, 1975
Pan American Medical Association, 1975-76
American Thoracic Society, 1977-81
Collegium Ramazzini, 1983-
Society for Risk Analysis, 1987-

Participation on Advisory Panels

Federal, State and Local Government

Allegheny County, Pennsylvania Air Pollution Advisory Committee, 1967-72; Chairman, Air Quality Subcommittee, 1967-69
USPHS, National Air Pollution Control Administration, Air Pollution Research Grants Advisory Committee, Member, 1968-72; Chairman, 1969-72
National Research Council, National Academy of Sciences Committee on Biological Effects of Air Pollution, Member 1970-71
U.S. Department Health, Education and Welfare, NIH, Special Studies Section (Grants Review), Member, 1974-75
National Research Council, National Academy Engineering Committee on Air Pollution and Stationary Source Control, Member, 1974-75
Environmental Protection Agency, Science Advisory Board, 1975; 1977-81; 1982-85
National Institute of Occupational Safety and Health, Testing and Certification Committee, 1979

PROFESSIONAL ACTIVITIES

Participation on Advisory Panels

Federal, State and Local Government (cont'd)

National Advisory Committee on Vital and Health Statistics, DHEW, Washington, DC 1979-81
National Academy of Sciences, Committee on Institutional Means of Risk Assessment, 1981-82
Office of Technology Assessment Committee on Control Technologies in the Workplace, Chairman, 1982-83
Governor's Toxic Substances Advisory Board, State of Maryland, 1982-85
Office of Technology Assessment, Committee on Cleanup of Uncontrolled Hazardous Waste Sites Under Superfund, 1983-85
National Science Foundation Project on State of the Art of Risk Assessment, Member of Advisory Committee, 1984
Thermal Insulation Manufacturers Association, Member, Advisory Committee, 1984
Maryland Long Range Environmental Planning Committee, State of Maryland, Baltimore, MD, 1985-87
Clean Sites, Incorporated, Alexandria, VA, (Chair, Technical Advisory Board), 1985-88
National Cancer Institute, Advisory Board on Methylene Chloride Epidemiological Study, Member, 1986-87
Mine Health Advisory Committee, Member. National Institute of Occupational Safety and Health, Atlanta, GA, 1986-89
GM/UAW Health Advisory Committee, Detroit, MI, 1988-92
Governor's Toxic Council, State of Maryland, Chair, 1986-89; Member, 1990-1991
Office of Technology Assessment Committee on Cleanup of DOE Weapons Production Sites, Member, 1989-90
Office of Technology Assessment, Committee on Economic Aspects of OSHA Regulation, Member, 1993
Department of Energy, Tank Advisory Panel (Hanford Site), Pascoe, WA, 1993-

Consultations

Governmental Agencies

U.S. Atomic Energy Commission, Division of Biology and Medicine, Washington, DC, 1964-66; Oak Ridge National Laboratory, 1964-66; Los Alamos Scientific Laboratory, Industrial Hygiene Group, 1964-; Idaho Falls Reactor Test Site, Health and Safety Division, 1967
U.S. Public Health Service, Division of Air Pollution, Laboratory of Engineering and Physical Sciences, 1964-68

EXHIBIT "B"

Mark R. Wick, M.D., F.C.A.P., F.A.S.C.P., F.A.S.D.
301 Peacock Drive
Charlottesville, Virginia 22903-9716
Telephone 804-245-9613; FAX 804-245-9643; E-mail– mrwick1@usa.net

January 28, 2000

Mr. Michael Beers
Paralegal
c/o Jenkens & Gilchrist
Attorneys at Law
1445 Ross Avenue, Suite 3200
Dallas, Texas 75202
FAX 214-855-4300

RE: Willie Moore (DOB 7-5-38; DOD 9-19-95; SSN 453-62-4414)

Dear Mr. Beers,

I have had the opportunity to study the materials that were sent to me in the above-cited case, that of the late Mr. Willie Moore. I received 29 glass slides and one paraffin block (which was largely devoid of tissue), all labeled SD94-4462, from Diagnostic Center Hospital, Houston, TX.

You will recall that Mr. Moore was 56 years old when he consulted his physician with complaints of shortness of breath and right-sided chest pain. Chest radiographs showed a large right pleural effusion; the left lung and pleura were within normal limits. Cytologic examination of thoracentesis fluid was unrevealing, and the patient underwent thoracoscopy with pleural biopsy. This procedure yielded a diagnosis of malignancy, and Mr. Moore subsequently had a right extrapleural pneumonectomy in December 1994. This was followed by chemotherapy; nevertheless, the patient had a recurrence of his tumor in April 1995 and died the following September.

Pathologic review of the specimens listed above shows a spindle-cell malignancy of the right pleura and thoracic soft tissue, having the morphologic characteristics of a sarcomatoid malignant mesothelioma. This impression was apparently confirmed by immunohistologic studies (not sent for my review), reportedly showing positivity for keratin, vimentin, and calretinin, with no labeling for CD15, CEA, B72.3, S100 protein, or Ber-EP4. Fragments of fibrohyaline pleural plaque are also entrapped in the tumor tissue. The non-neoplastic lung tissue demonstrates rare asbestos bodies, best seen on iron stains of block A7, but no interstitial fibroelastosis is present. Mild to moderate centrilobular emphysema and anthracosis are also evident. Lastly, the intrathoracic lymph nodes demonstrate prominent non-necrotizing

Mark R. Wick, M.D.

granulomatous inflammation, which, in the face of negative AFB and GMS stains, is most consistent with a diagnosis of sarcoid-like granulomatosis.

In regard to the causation of the mesothelioma in this case, the presence of fibrohyaline pleural plaques indicates that it is related to asbestos exposure. Moreover, I believe that the particular period of exposure in question that accounted for the tumor can be identified as well. The patient was in the U.S. Navy as an electrician from 1956 to 1960, during which time his answers to interrogatories indicate that he worked with asbestos products in an unprotected fashion. In contrast, Mr. Moore related in the same interrogatories that his subsequent employment at Champion International (Lufkin, TX) from 1961 to 1995 was characterized by protection with a respirator or a similar protective device. Thus, to a reasonable degree of medical certainty, my conclusions in this case are threefold:

1. Mr. Moore died of a sarcomatoid pleural mesothelioma;
2. That tumor was caused by asbestos exposure; &
3. The causative exposure was that obtained during Mr. Moore's military service in the U.S. Navy, from 1956 to 1960.

I hope that this information is of interest. All materials will be returned to your office under separate cover, by courier mail.

Sincerely,

Mark R. Wick, M.D., F.C.A.P., F.A.S.C.P., F.A.S.D.

MRW:jmw